Under the Auspices of:
FIT FOR FUTURE - HELP HEALING THE WORLD
Asian and Pacific Federation of Clinical Biochemistry
21 International Congress of Clinical Chemistry and
Laboratory Medicine
st
19 IFCC-EFCC European Congress of Clinical
Chemistry and Laboratory Medicine
th
Clinical and Laboratory Standards Institute
8 Annual Meeting of the German Society of Clinical
Chemistry and Laboratory Medicine
th
Berlin, Germany
ICC Berlin - Internationales Congress Centrum
15 - 19 May 2011
FINAL PROGRAM
World Association of Societies of Pathology and Laboratory Medicine
Bundesministerium für Bildung und Forschung
SUNDAY 15 MAY
17.30 - 19.30
OPENING CEREMONY
HALL 1
MONDAY 16 MAY
9:00-11:00
SYMPOSIUM 1
HALL 1
BIOMARKERS FOR THE DIAGNOSIS OF CARDIOVASCULAR DISEASES
9:00-11:00
SYMPOSIUM 2
HALL 3
DIAGNOSTIC CHALLENGES IN LIVER DISEASE
HALL 14.2
16:45-17:45 Workshop HORIBA
THE “LEAN” ALTERNATIVE
14:30-16:00 INTERACTIVE 1
HALL 10
CHALLENGES AT THE CLINICAL INTERFACE
16:45-17:45 Workshop OSM
HALL 9
ZENTRALLABOR VS. VERBUNDLABOR
9:00-10:30
WORKSHOP 1
HALL 10
REPORTING HbA1c FOR MONITORING AND DIAGNOSIS: THE DEVIL’S IN THE DETAIL
13:00 - 14:00 Workshop ORTHO
HALL 8
CLINICAL DIAGNOSTICS
TESTING FOR VITAMIN D DEFICIENCY: DEFINING AT-RISK POPULATIONS
13:00 - 14:00 Workshop BECKMAN HALL 14.2
COULTER
CLINICAL AND ECONOMIC ADVANCES IN PROSTATE CANCER DIAGNOSIS
13:00 - 14:00 Workshop ABBOTT
HALL 7
IMPORTANCE OF BIOMARKERS IN OPTIMISING THE TREATMENT OF PATIENTS WITH
HEART AND KIDNEY DISEASE
13:00 - 14:00 Workshop SYSMEX
HALL 4/5
TRUST BY VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS
9:00-11:00
YEAR IN REVIEW 2
HALL 3
ADVANCES IN CLINICAL CHEMISTRY IN THE FIELD OF NEPHROLOGY AND
ENDOCRINOLOGY
13:00 - 14:00 Workshop ZMBD
HALL 10
IMPACT OF NEW OMICS-PLATFORMS ON BIOMARKERS DISCOVERY AND
APPLICATIONS
POSTER AREA
14:15-15:15 Workshop RANDOX
HALL 14.2
THE CLINICAL UTILITY OF MULTIPLEX BIOCHIPS FOR THE DETECTION OF MULTIPLE
STI’S AND RESPIRATORY PATHOGENS
14:15-15:15 Workshop A.MENARINI HALL 4/5
SEDIMAX: RECENT AND SIGNIFICANT ADVANCES IN AUTOMATED URINE SEDIMENT
EXAMINATION
14:30-16:30 SYMPOSIUM 5
HALL 1
FROM BENCH TO BEDSIDE IN AUTOIMMUNITY
HALL 4/5
14:30-16:30 DGKL 2
HALL 9
LABORATORY MEDICINE - QUO VADIS?
CONDITIONS, STRUCTURES AND DEVELOPMENTAL TRENDS IN EUROPE
14:30-16:00 INTERACTIVE 2
HALL 10
PITFALLS IN THE HEMOSTASIOLOGIC DIAGNOSTICS: CLINICAL CASES
15:30-16:30
Workshop ORTHO
HALL 8
CLINICAL DIAGNOSTIC
ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA IN EUROPE
15:30-16:30 Workshop SARSTEDT HALL 4/5
WORKFLOW OPTIMISATION BY FRONT AND BACK END AUTOMATION IN THE
DIAGNOSTIC LABORATORY
15:30-16:30 Workshop BIOSYSTEMS
HALL 4/5
TRACEABILITY AND UNCERTAINTY OF CATALYTIC ACTIVITY MEASUREMENTS
16:45-17:45 Workshop SIEMENS
HALL 9
NEW HIGH-PERFORMANCE ASSAYS FOR THE DETERMINATION OF FREE LIGHT
CHAIN KAPPA AND LAMBDA - ADDING CONSISTENCY TO MONITORING AND
SCREENEING OF MULTIPLE MYELOMA
16:45-17:45 Workshop PERKINELMER
HALL 10
CLINICAL MSMS - NEW DEVELOPMENTS IN TODAY’S LABORATORY
WEDNESDAY 18 MAY
THURSDAY 19 MAY
9:00-11:00
SYMPOSIUM 17
HALL 1
NEW STRATEGIES IN MOLECULAR DIAGNOSTIC
9:00-11:00
SYMPOSIUM 18
HALL 3
STANDARDIZATION AND QUALITY CONTROL ISSUES IN EMERGING AND
DEVELOVING COUNTRIES
9:00-10:30
WORKSHOP 10
HALL 8
STANDARDIZATION OF COMPLEX ANALYTE MEASUREMENT: THE CLINBIOTRACE
PROJECT
9:00-11:00
SYMPOSIUM 12
HALL 1
BIOMARKERS IN ACUTE AND CHRONIC BRAIN DISEASES
9:00-11:00
SYMPOSIUM 19
HALL 14.2
CURRENT CHALLANGES IN THE PEDIATRIC LABORATORY
9:00-11:00
YEAR IN REVIEW 3
HALL 3
DEVELOPMENTS IN CLINICAL LABORATORY PRACTICE
9:00-11:00
EFCC 4
HALL 7
STANDARDIZATION OF THE PRE-ANALYTICAL PHASE FOR BIOMARKERS
9:00-10:30
WORKSHOP 7
CLINICAL PHARMACOGENETIC
9:00-11:00
SYMPOSIUM 20
VITAMIN D: MYTH OR MAGIC
HALL 8
HALL 4/5
9:00-11:00
SYMPOSIUM 13
HALL 14.2
PRENATAL AND NEONATAL SCREENING
9:00-10:30
WASPaLM WS
HALL 9
CHRONIC KIDNEY DISEASE - DEVELOPING A NATIONAL TESTING PROGRAM
9:00-10:30
WORKSHOP 4
HALL 10
UPDATE ON CARDIAC TROPONIN - CLINICAL AND LABORATORY ISSUES
9:00-11:00
IFCC 3
HALL 7
STANDARDIZATION IN MOLECULAR DIAGNOSTICS
9:00-10:30
WORKSHOP 11
HALL 10
BIOMARKERS OF ACUTE AND NEURODEGENERATIVE BRAIN DAMAGES
11:30-12:45
PLENARY SESSIONS HALL 1
ADVANCES IN CLINICAL AND DIAGNOSTIC IMMUNOLOGY
9:00-11:00
SYMPOSIUM 14
ALLERGY DIAGNOSTICS
11:30-12:45
PLENARY SESSIONS HALL 1
NEW AVENUES IN LABORATORY DIAGNOSTICS
13:00 - 14:00 Workshop RANDOX
HALL 8
INCREMENTAL VALUE OF H-FABP IN AN AREA OF HIGHLY SENSITIVE TROPONINS
9:00-11:00
DGKL 5
HALL 9
DEVELOPMENT OF A TRANSCRIPTOMIC, PROTEOMIC AND METABOLOMIC
DATABASE FOR HUMAN BLOOD CELLS
13:00 - 14:00 Workshop LABS ARE
HALL 8
VITAL
ADDING VALUE TO LABORATORY MEDICINE
9:00-10:30
WORKSHOP 8
HALL 10
MOLECULAR DIAGNOSIS OF INFECTION
13:00 - 14:00 Workshop WATERS
HALL 9
LC/MS IN THE CLINICAL LABORATORY TRANSITION FROM A RESEARCH TOOL TO ROUTINE CLINICAL LABORATORY USE
13:00 - 14:00 Workshop ABBOTT
HALL 7
LABORATORY DIAGNOSIS OF HEPATITIS C - WHAT ARE LOOKING FOR?
HALL 4/5
11:30-12:45
PLENARY SESSIONS HALL 1
THE BRAIN: BIOLOGICAL AND CEREBRAL DISEASES
14:30-16:30 SYMPOSIUM 21
HALL 1
NEW TECHNOLOGIES IN CLINICAL APPLICATION
13:00 - 14:00 Workshop RANDOX
HALL 8
THE USE OF MULTIPLEX ASSAYS FOR DETERMINING PREDISPOSITION TO
HYPERTENSION
14:30-16:30 SYMPOSIUM 22
HALL 3
INTERWINING EMERGENCY MEDICINE AND LABORATORY MEDICINE
13:00 - 14:00 Workshop BECKMAN HALL 14.2
COULTER
NOVEL MARKERS IN REPRODUCTIVE ENDOCRINOLOGY
14:30-16:00 WORKSHOP 12
HALL 8
TRENDS IN THERAPEUTIC DRUG MONITORING: PERSONALIZED
IMMUNOSUPPRESSION
13:00 - 14:00 Workshop ORTHO
HALL 10
CLINICAL DIAGNOSTIC
ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTICS ARENA IN EUROPE
13:00 - 14:00 Workshop ABBOTT
HALL 7
VITAMIN D AND B12 - IMMUNOASSAYS IN PREVENTIVE MEDICINE
14:30-16:30 IFCC 4
HALL 7
TRACEABILITY, STANDARDIZATION, HARMONISATION: CONCEPTS AND
IMPLEMENTATION
13:30 - 14:30
POSTER WALKS
13:00 - 14:00 Workshop SYSMEX
HALL 4/5
WORK AREA MANAGEMENT: THE ULTIMATE PRODUCTIVITY TOOL
13:00 - 14:00 Workshop SYSMEX
HALL 4/5
TRUST BY VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS
13:00 - 14:00 Workshop A.MENARINI HALL 9
FOCUS ON NEW DIAGNOSTIC STRATEGIES IN AUTOIMMUNITY
POSTER AREA
14:15-15:15 Workshop SIEMENS
HALL 4/5
DIAGNOSTIC AND CLINICAL IMPORTANCE OF MEASURING VITAMIN D TOTAL
14:30-16:30 EFCC 1
HALL 7
HOW TO ASSESS THE CLINICAL EFFECTIVENESS OF LABORATORY TESTS?
16:45-17:45 Workshop ABBOTT
HALL 7
AUTOMATION TO ENSURE YOUR LAB’S EFFICIENCY
15:30-16:30 Workshop RANDOX
HALL 14.2
CURRENT AND FUTURE PERSPECTIVES IN DRUGS OF ABUSE SCREENING; THE MULTIPLEX APPROACH
9:00-11:00
IFCC 2
HALL 9
BIOBANKING AND LABORATORY MEDICINE: TWO RESOURCES FOR MODERN
HEALTH CARE
Workshop BECKMAN HALL 14.2
COULTER
NEW HORIZONS IN CELLULAR ANALYSIS
14:30-16:00 WORKSHOP 2
HALL 8
EMERGING INFECTIONS AT AFCB COUNTRIES
16:45-17:45 Workshop ROCHE
HALL 14.2
PERSONALISED THERAPIES FOR CHRONIC HEPATITIS B AND C:
THE LEADING ROLE OF VIROLOGICAL MARKERS
9:00-11:00
DGKL 3
HALL 7
BIOCHEMICAL ANALYSIS PRIZE - AWARD CEREMONY
14:15-15:15
HALL 3
16:45-17:45 Workshop CHROMSYSTEMS
HALL 8
THERAPEUTIC DRUG MONITORING IN CLINICAL DIAGNOSTICS FROM RESEARCH TO ROUTINE
HALL 14.2
13:00 - 14:00 Workshop BECKMAN HALL 14.2
COULTER
FROM CLINICAL CHEMISTRY TO MOLECULAR DIAGNOSTICS: INNOVATIVE
SOLUTIONS FOR LABORATORY AUTOMATION AND ORGANISATION
13:00 - 14:00 Workshop SIEMENS
HALL 9
THE VALUE OF IMPROVED WORKFLOW SOLUTIONS
16:45-17:45 Workshop ROCHE
HALL 14.2
EFFICIENT LAB ORGANIZATION FROM PRE-TO POST ANALYTIC
Workshop BECTON
HALL 4/5
DICKINSON
COUNTING THE COST OF THE PREANALYTICAL PHASE
TUESDAY 17 MAY
9:00-11:00
SYMPOSIUM 9
HAEMATOLOGY AND ANEMIA
HALL 1
HALL 8
16:45-17:45
9:00-11:00
SYMPOSIUM 8
INFECTIOUS DISEASES
9:00-11:00
DGKL 1
HALL 9
ROLE OF NON-MEDICAL SCIENTISTS
14:30-16:30 SYMPOSIUM 6
DIABETES MELLITUS
16:45-17:45 Workshop SEBIA
HALL 4/5
HBA1C: EW BREAKTHROUGH TECHNOLOGY FOR LABORATORIES FACING A
CHANGE OF PARADIGM
9:00-10:30
WORKSHOP 3
HALL 8
OXIDATIVE STRESS IN DIABETES MELLITUS
9:00-11:00
SYMPOSIUM 4
HALL 4/5
ACUTE AND CHRONIC KIDNEY DISEASES. AN UPDATE
13:30 - 14:30
POSTER WALKS
14:30-16:30 DGKL 6
HALL 9
RESEARCH FUNDING BY THE FOUNDATION OF PATHOBIOCHEMISTRY AND MOLECULAR DIAGNOSTICS OF THE DGKL
9:00-11:00
SYMPOSIUM 7
HALL 1
PHARMACOGENETIC AND PHARMACOGENOMIC
9:00-11:00
IFCC 1
HALL 7
e-LEARNING AND DISTANCE EDUCATION IN CLINICAL CHEMISTRY AND LABORATORY MEDICINE
11:30-12:45
PLENARY SESSIONS
MOLECULAR TUMOR DIAGNOSTICS
15:30-16:30 Workshop IRIS
HALL 4/5
THE CLINICAL UTILITY OF REFLEX URINE CULTURES BASED ON URINALYSIS AND
AUTOMATED URINE MICROSCOPY USING THE IQ200 WORKSTATION
16:45-17:45 Workshop AXIS SHIELD
HALL 10
USING ACTIVE B12 TO DIAGNOSE VITAMIN B12 DEFICIENCY
9:00-11:00
YEAR IN REVIEW 1
HALL
CLINICAL CHEMISTRY 2010 AND BEYOND: OPPORTUNITIES AND CHALLENGES FOR
THE NEXT DECADE
9:00-11:00
SYMPOSIUM 3
TUMOR MARKERS IN CANCER
16:45-17:45 Workshop ABBOTT
HALL 7
OVARIAN CANCER BIOMARKERS IN THE CLINICAL CONTEXT - STRATIFICATION AND
MONITORING
14:30-16:30 SYMPOSIUM 10
HALL 1
DIAGNOSTIC USE AND VALUE OF FUCTION TEST IN ENDOCRINOLGY
14:30-16:30 SYMPOSIUM 11
HALL 3
POINT OF CARE TESTING - PRACTICAL ASPECTS
14:30-16:00 WORKSHOP 5
HALL 8
LESSONS FROM ASIAN-PACIFIC MULTICENTER REFERENCE INTERVAL STUDY
14:30-16:30 DGKL 4
HALL 7
QUALITY MANAGEMENT ACCORDING TO THE GERMAN RILIBAEK:
AN INTERNATIONAL PERSPECTIVE
14:30-16:30 EFCC 2
HALL 9
ACCREDITATION SHOULD BE FOCUSSED ON MORE THEN WELL ORGANIZED
EXAMINATIONS WITHIN THE LABORATORY
14:30-16:00 WORKSHOP 6
HALL 10
THE 2009 INFLUENZA PANDEMIC - LESSONS LEARNED
15:30-16:30 Workshop ROCHE
HALL 14.2
NEXT GENERATION IN CARDIAC BIOMARKERS: LABORATORY MEDICINE’S CONTRIBUTION TO INDIVIDUALIZED TREATMENT IN ACS AND HEART FAILURE
13:00 - 14:00 Workshop THE
HALL 9
BINDING SITE
TM
TM
Freelite AND Hevylite IN MONOCLONAL GAMMAPATHIES: IMPROVING DIAGNOSIS,
MONITORING AND PROGNOSIS ASSESSMENT
13:00 - 14:00 Workshop DIASORIN
HALL 10
VITAMIN D DIETARY REFERENCE INTAKES: IMPLICATIONS AND SIGNIFICANCE IN
CLINICAL PRACTICE
13:30 - 14:30
POSTER WALKS
14:30-16:00 WORKSHOP 13
HALL 9
VITAMIN DEFICIENCY IN ELDERLY PEOPLE: DIAGNOSIS, PREVENTION AND EFFECT
ON AGE-RELATED DISEASES
14:30-16:00 WORKSHOP 14
HALL 10
NOVEL INSIGHTS IN IRON METABOLISM: IMPLICATIONS FOR DIAGNOSTIC MEDICINE
16:30-17:30
CLOSING CEREMONY
HALL 1
POSTER AREA
14:15-15:15 Workshop ROCHE
HALL 14.2
PERSONALISED HEALTHCARE AS A KEY DRIVER FOR PRESENT AND FUTURE
DIAGNOSTIC/THERAPEUTIC STRATEGIES
14:15-15:15 Workshop DIASYS
HALL 4/5
A NEW PROSPECTIVE FOR THE AUTOMATION OF CLINICAL CHEMISTRY TESTING
14:30-16:30 SYMPOSIUM 15
HALL 1
NEW DEVELOPMENTS IN HAEMOSTASEOLOGY
14:30-16:30 SYMPOSIUM 16
HALL 3
CONTRIBUTION OF LABORATORY MEDICINE IN LEUKEMIA
14:30-16:00 WORKSHOP 9
HALL 8
WHAT PAPERS WILL BE PREFERRED IN THE FUTURE RELATED TO LABORATORY
MEDICINE?
SOCIAL EVENTS
Sunday 15 May
19:30 Welcome Party
Monday 16 May
20:00 Presidents’ Dinner at Adlon Hotel
By invitation only
Wednesday 18 May
19:30 Congress Party at Museum Island
14:30-16:30 EFCC 3
HALL 7
A SCIENTIFIC APPROACH TO THE POST-ANALYTICAL PHASE
- At a glance-
Printed as of April 2011
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Welcome to the IFCC-WorldLab-EuroMedLab Berlin 2011
IFCC - International Federation of Clinical Chemistry and Laboratory Medicine
EFCC - European Federation of Clinical Chemistry and Laboratory Medicine
DGKL - German Society of Clinical Chemistry and Laboratory Medicine
Welcome from Local Authorities
Committees
Executive Boards
Travel Grants
S CI E NTIF
NTI F I C P R O G R A M
Sunday 15 May
Monday 16 May
Tuesday 17 May
Wednesday 18 May
Thursday 19 May
Speakers and Chairs
P O S TE R S
Information and Map
Poster List
G E NE RA L I N F O R M AT I O N
Information
Social Events
Tourist Information
S P O NS OR
RS
O R S & E X H I B I TO
TORS
Conte nts
W E LCO M E A D D R E S S E S
and CO M M I T T E E S
pages 2 - 10
2
3
4
5
6
8
9
10
p a g e s 11 - 9 0
12
15
34
53
68
80
pages 93 - 172
94
97
pages 175 - 188
176
185
187
pages 190 - 257
Platinum Sponsors
Gold Sponsors
Bronze Sponsors
Exhibitors
Sponsors
Exhibition Area Maps
191
194
195
201
249
250
Program at a glance
Front fold out
1
Preside nts ’ We l c ome
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Dear Participants of IFCC-WorldLab-EuroMedLab Berlin 2011,
Dear Colleagues and Friends,
It is with great pleasure to welcoming you here in Berlin, the capital of
reunited Germany!
It is a great privilege and honour for us to host this major joint event of
Laboratory Medicine and Clinical Chemistry here in our country. The 21st
International Congress of Clinical Chemistry and Laboratory Medicine will
take place together with the 19th European Congress of Clinical Chemistry
and Laboratory Medicine as well as with the 8th Annual Meeting of the
German Society of Clinical Chemistry and Laboratory Medicine.
We would like to thank the International Scientific Committee (ISC) in
bringing together a highly attractive and up-to-date scientific program,
consisting of 12 plenary lectures in four sessions, 22 symposia, interactive
sessions, 14 workshops and more than 40 industry-sponsored workshops.
Altogether we have invited more than one hundred speakers from around
the world to deliver to you all facets of our discipline ranging from basic
science and translational research to clinical practice.
In addition to these classical types of scientific sessions, we will also offer new types of formats
such as “The Year in Review”, “Clinical Case Conferences” and other highly interactive formats
to discuss cutting-edge science in our field.
In addition to science, Berlin is one of the most vibrant cities in Germany and Europe and
represents, therefore, an ideal platform to provide not only an international exchange of
knowledge and ideas, but also to foster friendship and collegiality among the participants from
around the world. In addition to the scientific program, a rich social program providing the frame
for relaxation and cultural stimulation has been developed for attendees, families and friends.
Particularly, we would like to draw your attention to the Congress Evening on Wednesday with
an exclusive visit to the Museum Island, a World Heritage.
The motto of our conference, Fit for future - Help healing the World, emphasizes and
underscores the importance of laboratory medicine in patient care. However, we all know that
this goal is very ambitious and many research efforts are necessary to eventually reach this
equation.
The realization of this Congress is only possible with the generous support of the Diagnostic
Industry. We would like to thank all sponsoring companies for their help and willingness to actively
participate in this event. Please use the time slots for visiting the large exhibition area which
offers a view on the most recent technological and diagnostic advancement in laboratory
medicine!
Therefore, a warm welcome to Berlin!
Harald Renz
President
2
Rudolf Tauber
President
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
The International Federation of Clinical Chemistry and Laboratory Medicine
(IFCC) is proud to host IFCC WorldLab Berlin 2011.
IFCC is a global professional organization serving a worldwide partnership of
clinical laboratory scientists, laboratory physicians and specialists within the
in-vitro diagnostics industry. Founded in 1952 the IFCC membership currently
comprises 85 national societies and 42 companies who together represent
more than 30,000 laboratory medicine specialists.
The IFCC mission statement is: “Through leadership and innovation in science
and education:
• We strive to enhance the scientific level and the quality of diagnosis and therapy for patients
throughout the world
• We build on the professionalism of our members to provide quality services to patients
• We communicate effectively with our members, other healthcare providers and the public to ensure
knowledge of our excellent scientific and educational achievements
• We focus on scientific standards, publications, education and communications
• We hold outstanding congresses and conferences throughout the world to bring the efforts of IFCC
to the global community.
The current priorities for IFCC are:
• To complement and enhance the activities of its members
• To share examples of good practice and to promote the contribution and added value of clinical
chemistry and laboratory medicine
• To transcend geographical and corporate boundaries by developing global programmes for clinical
chemistry and laboratory medicine
• Through the Scientific Division (SD) to provide a forum for standardization and traceability, with the
establishment of reference systems to improve the quality of health care for individuals and
communities
• Through the Education and Management Division (EMD) to provide IFCC members and the
healthcare community with relevant education directed at clinical, scientific, and management issues,
especially in developing countries
• Through the Communication and Publications Division (CPD) to communicate and promote the work
and image of IFCC to clinical laboratory scientists, physicians and health care policy makers worldwide.
The IFCC has extensive co-operation and direct collaboration with a large number of international
organizations which are active in clinical, scientific and educational areas of common interest.
The Officers of IFCC are always keen to communicate with members, other organizations and with
individuals on matters relating to clinical chemistry and laboratory medicine. Please visit the IFCC
website (www.ifcc.org) and/or contact the President, Graham Beastall (president@ifcc.org) or the
Secretary, Paivi Laitinen (secretary@ifcc.org).
Graham Beastall
IFCC President
3
I FCC
International Federation of Clinical
Chemistry and Laboratory Medicine
E FCC
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
European Federation of Clinical Chemistry
and Laboratory Medicine
Dear Colleagues,
It is a pleasure to welcome you at the joint IFCC WorldLab and EuroMedLab
Congress 2011 in Berlin, the second most populous and one of the most
vibrant cities of Europe. Berlin is among the top three convention cities in
the world, where research and development have established economic
significance, and the Berlin Brandenburg region ranks among the top three
innovative regions in the European Union.
Thus there is no doubt that Berlin, with its history and resources, provides
an infrastructure which enables all attendees to meet their needs and to enjoy the scientific,
cultural and social opportunities that this Congress offers. As one would expect there is a wideranging high quality scientific program covering the cutting-edge developments in laboratory
medicine. The scientific program of the Congress demonstrates the invaluable role that Laboratory
Medicine plays in health care. Main conference topics include the role of prevention, theragnostics,
new technologies and biomarkers in the era of "omics", the relevance of automation and IT, and
the education and training of our future professionals to cope with these challenges, particularly
in a demanding and difficult economic environment.
This conference will be an opportunity to meet old friends and make new ones to interact with
like-minded colleagues in the pursuit of common goals and interests in the ongoing development
of clinical chemistry and laboratory medicine.
After the fall of the Berlin Wall in November 1989 the Brandenburg Gate, enhancing the approach
into the Boulevard Unter den Linden, became not only a historical landmark but also the symbol
of unity. So, let us unite the profession in Europe and all over the world in the exciting city of
Berlin!
Whether on the congress floor or sampling the attractions of Berlin, I am sure you will enjoy your
attendance at a memorable meeting. EFCC welcomes you for an enriching professional
conference and friendly exchanges Unter den Linden!
Andrea Rita Horvath
EFCC President
4
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
DG KL
German Society of Clinical Chemistry and
Laboratory Medicine
Dear Delegates,
dear Colleagues,
It is my pleasure to welcome you to the 21st International Congress of Clinical
Chemistry and Laboratory Medicine in Berlin organized by IFCC, EFCC, and
DGKL. As one of the oldest scientific societies devoted primarily to this field
of medicine we are proud to host scientists from all over the world on this
occasion. The congress presidents Harald Renz and Rudolf Tauber
supported by an international congress organizing committee and a scientific
advisory board have assembled a program delineating the state of the art of
our profession. Looking at the final program it is clear that the hard work of the last three years
has led to what can be expected from an outstanding congress. It will underscore the immense
impact of laboratory diagnostics on all areas of modern medicine. During the congress there will
be ample opportunity for scientific exchange among the delegates and with the invited speakers.
Plenary sessions, parallel symposia, industry sponsored workshops, and poster sessions provide
the stage for in depth discussions, and I encourage you to take this opportunity. During the meeting
the IFCC, EFCC, and DGKL will also award their renowned prizes for scientific and professional
achievements among them the Biochemical Analysis Prize of the DGKL with a tradition of more
than 40 years. Among the list of prize winners are 5 scientists who were later awarded the Nobel
Prize.
All this is embedded in the vibrant city of Berlin which offers a wealth of cultural experiences. One
of them – the world famous Museum Island – will open its doors exclusively for congress delegates
and their company on Wednesday evening. You will have time to visit the unique treasures among
them the Pergamon Altar and Nefertiti. I expect this to become an unforgettable congress highlight.
I wish that all of you enjoy your stay in Berlin and remember the congress as an exciting and
stimulating scientific event that was well worth the travel.
Karl J. Lackner
President DGKL
5
We l c ome
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Message from the Federal Minister of Education
and Research,
Annette Schavan
Increasingly detailed knowledge about the causes of diseases and new
diagnostic technologies are vital prerequisites for medical innovations.
Modern laboratory equipment contributes to diagnosing diseases more
quickly, more reliably and at an earlier stage. As a result, treatment can be
initiated more promptly and in a more targeted way. The aim of
individualized medicine is to choose the therapy that is best suited to the
patient, avoiding side effects wherever possible. More precise diagnostic
tools do not just enable individually tailored treatments - innovative
laboratory diagnostics and bioinformatics also change the way in which new
drugs are developed.
Health research plays an important role in the Federal Government's High-Tech Strategy: since
2007, approximately 800 million euros have been provided for efforts to strengthen basic
research and accelerate the transfer of research results to the treatment of patients. During
this period, the Federal Ministry of Education and Research has invested 30 million euros in
molecular diagnostics alone to ensure that Germany remains a competitive, forward-looking
research location in the field of laboratory medicine. After all, the molecular diagnostics market
is also important from an economic point of view. It is currently worth 12 billion euros, and
experts predict that it will grow to approximately 22.5 billion euros over the next five years.
We are facing great challenges in the 21st century - particularly in the field of health research.
Demographic change and the rapidly increasing prevalence of certain diseases pose great
challenges in the area of health research. To meet them, we need modern health research in
all fields of science, and we expect a great deal from the area of laboratory medicine. I would
like to thank the organizers of this year's International Congress of Clinical Chemistry and
Laboratory Medicine in Berlin for their great commitment. I hope that the event will provide a
forum for interesting conversations and discussions, stimulate new ideas for future research
activities, and present important information for medical practitioners.
Prof. Dr. Annette Schavan
Federal Minister of Education and Research
6
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
for the IFCC WorldLab 2011 in Berlin
IFCC WorldLab EuroMedLab is one of the world’s largest and most
important scientific congresses, and Berlin is greatly honored to be hosting
the national and international experts working in this field. You will feel at
home in Berlin, which is a city of great scientific capability.
Medicine, research, and academics occupy a special position in Berlin.
Universities and many non-university research institutes of international
renown work together closely here. Networks within disciplines promote
cooperation between science and business, and many of our medical
products and services are unique in their fields.
Berlin is very well prepared to host large national and international
congresses and trade fairs. The International Congress Center (ICC); Messe Berlin, our trade
fair company; and many other conference facilities offer excellently equipped premises for
concentrated professional interaction, and Berlin's hotels and atmospheric restaurants offer
inviting opportunities for culinary exploration.
Those attending a conference on the banks of the Spree should not forget to take a look at the
city's cultural calendar. Whether theater or opera, classical music or jazz, ancient sculpture or
contemporary art – Berlin has something for everyone.
Berlin is welcoming the IFCC WorldLab-EuroMedLab participants.
Klaus Wowereit
Governing Mayor of Berlin
7
We l c ome
Message from the Governing Mayor of Berlin, Klaus Wowereit,
Commit t ees
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
CONGRESS ORGANIZING COMMITTEE
T. Brinkmann (Switzerland)
J. Klabunde (Germany)
K.J. Lackner (Germany)
T. Ozben (Turkey)
H. Renz (Germany)
R. Tauber (Germany)
INTERNATIONAL SCIENTIFIC COMMITTEE
H. Renz (Germany) - Chairman
R. Tauber (Germany) - Vice Chairman
V. Blaton (Belgium)
K. Brand (Germany)
T. Brinkmann (Switzerland)
B. Croal (United Kingdom)
A. Hedili (Tunisia)
J. Hicks (USA)
A.R. Horvath (Hungary)
K.J. Lackner (Germany)
C. Lam (Hong Kong)
D. Mazziotta (Argentina)
H. Morris (Australia)
M. Neumaier (Germany)
T. Nobori (Japan)
T. Ozben (Turkey)
M. Panteghini (Italy)
M. Pilonetto (Brazil)
K. Pulkki (Finland)
R. Sierra Amor (Mexico)
C. Wagener (Germany)
U. Walter (Germany)
J. Wesenberg (Canada)
M.A. Zablitt (Lebanon)
INTERNATIONAL SCIENTIFIC ADVISORY BOARD
H. Renz (Germany) - Chairman
A.A. Bulo (Albania)
A. Hooper (Australasia)
A. Griesmacher (Austria)
J.P. Chapelle (Belgium)
K. Tzatchev (Bulgaria)
P. St. Louis (Canada)
E. Aranda (Chile)
A. Simundic (Croatia)
T. Zima (Czech Republic)
K. Tomberg (Estonia)
K. Pulkki (Finland)
P. Gillery (France)
A. Chaliassos (Greece)
H.M. Chan (Hong Kong)
A.R. Horvath (Hungary)
J.J. Jonsson (Iceland)
P. Mocarelli (Italy)
M. Plebani (Italy)
T. Nobori (Japan)
Y.Y. Bilto (Jordan)
J.Q. Kim (Korea)
O.H. Kwon (Korea)
G. Gilson (Luxemburg)
J.F. Muñoz Valle (Mexico)
8
D. Popovic (Montenegro)
D.W. Swinkels (The Netherlands)
M.A. Charles-Davies (Nigeria)
A.L. Biorke Monsen (Norway)
M.M. Blanes Gonzalez (Paraguay)
J. Ortellado de Canese (Paraguay)
G. Sypniewska (Poland)
G. de Sousa (Portugal)
G. Benga (Romania)
M. Cojocaru (Romania)
V.V. Menshikov (Russia)
N. Majkic-Singh (Serbia)
K. Danova (Slovakia)
V. Steenkamp (South Africa)
J.M. Queralto (Spain)
E. Theodorsson (Sweden)
A. von Eckardstein (Switzerland)
L. Risch (Switzerland)
F. Harb (Syrian Arab Republic)
A. Hedili (Tunesia)
N. Ozer (Turkey)
M. Hallworth (United Kingdom)
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
G. Beastall (United Kingdom) - President
C. Lam (Hong Kong) - Vice-President
J. M. B. Hicks (USA) - Past President
P. Laitinen (Finland) - Secretary
G. Shannan (Syria) - Treasurer
T. Brinkmann (Switzerland) - Corporate Representative
B. Gouget (France) - Member
J. B. Lopez (Malaysia) - Member
U. Tuma (Brazil) - Member
EFCC - European Federation of Clinical Chemistry and Laboratory
Medicine
A. R. Horváth (Australia) - President
I. D. Watson (United Kingdom) - President-Elect
V. Blaton (Belgium) - Past President
H. J. van Pelt (The Netherlands) - Secretary
P. Schuff-Werner (Germany) - Treasurer
M. Pazzagli (Italy) - Member-at-large
K. Pulkki (Finland) - Member-at-large
DGKL - German Society for Clinical Chemistry and Laboratory Medicine
K. Lackner (Germany) - President
J. Thiery (Germany) - Vice-President
K. Kohse (Germany) Secretary
H. Patscheke (Germany) - Treasurer
R. Lichtinghagen (Germany) - Additional Member
J. Aufenanger (Germany) - Additional Member
Execu t ive Boards
IFCC - International Federation of Clinical Chemistry and Laboratory
Medicine
ORGANIZING SECRETARIAT
M
C
O
N
G
R
E
S
ila
S
no
I
MZ Congressi s.r.l.
Member of the MZ International Group (Milano, Torino, Barcelona, London)
Individual Company subject to management and coordination by MZ International Group srl
Sistema di Gestione certificato secondo la Norma ISO 9001:2008
Via Carlo Farini 81 - 20159 Milano, Italy
Phone +39 02 66802323 - Fax +39 02 6686699
e-mail: info@berlin2011.org
9
Travel Gran t s
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
WINNERS
ESSIARAB FADWA
GUPTA MONIKA
NEPAL ASHWINI
REVERENDO MARIA AMELIA
SHRESTHA ROJEET
AJILI FAOUZIA
CORT AYSEGUL
DUJIC TANJA
EL BAZ HATIM
JACOBS LEO
WAFULA BRAMWEL BARAZA
ISFER OLIVEIRA MAUREN
SZOKE DOMINIKA
BRAGA FEDERICA
ARPPE RIIKKA
DMYTRUK IRINA
OOSTENDORP MARLIES
FOROUGHI FOROUGH
CULEJ JELENA
DZIEGIELEWSKA SYLVIA
MOHAN TEENA
K I N D LY SU P P O R T E D B Y:
10
MOROCCO
INDIA
NEPAL
ARGENTINA
NEPAL
TUNISIA
TURKEY
BOSNIA
EGYPT
THE NETHERLANDS
KENYA
BRAZIL
ITALY
ITALY
FINLAND
UCRAINA
THE NETHERLANDS
IRAN
CROATIA
POLAND
INDIA
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Scientific
Scientific Program
Program
Sunda y 1 5 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
17:30 - 19:30
HALL 1
OPENING CEREMONY
Musical Introduction
A Time to Make Good Friends.
Welcome to Germany! Welcome to Berlin!
Berlin Symphony
Welcome Addresses
Congress Presidents, Rudolf Tauber, Harald Renz
IFCC President, Graham Beastall
EFCC President, Andrea Rita Horvath
DGKL President, Karl Lackner
Fit For Future
Help healing the World
“Heal the world”
Berliner Rundfunk Kinderchor & Jugendorchester
Awards Presentation
IFCC Distinguished Clinical Chemist Award - Sponsored by Beckman Coulter
IFCC Henry Wishinsky Award for Distinguished International Services Sponsored by Siemens
IFCC Award for Distinguished Contributions in Education - Sponsored by Abbott Diagnostics
IFCC Award for Significant Contributions in Molecular Diagnostics Sponsored by Abbott Molecular
IFCC Distinguished Award for Laboratory Medicine and Patient Care - Sponsored by IFCC
IFCC Robert Schaffer Award for Outstanding Achievements in the Development of
Standards for Use in Laboratory Medicine - Sponsored by NIST - CLSI
IFCC Young Investigator Award - Sponsored by Roche
EFCC Scientific Award for Laboratory Medicine - Sponsored by Roche
EFCC Labs Are Vital Award for Excellence in Outcomes Research in Laboratory Medicine Sponsored by Abbott
DGKL Prize “Biochemical Analysis” - Sponsored by Sarstedt
“We are the world”
Berliner Rundfunk Kinderchor & Jugendorchester
Opening Lecture
The Evolution of Medicine to Evolutionary Medicine
Detlev Ganten
Drumshow
Berlin Drum Company
After the opening ceremony, you are kindly invited to take part in the Welcome Party.
12
Follow the Presidents of the Congress and the Berlin Drum Company !!
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
The Evolution of Medicine to Evolutionary Medicine
Detlev Ganten (Germany)
President World Health Summit - Charité - Universitätsmedizin Berlin
Professor Ganten was born in Lüneburg in 1941. He studied medicine at
the universities of Würzburg, Montpellier (France) and Tübingen. After
taking his degree, he spent several years as a research scientist at the
Clinical Research Institute in Montreal (Canada), and earned his Ph.D. at
McGill University. In 1975 Detlev Ganten was appointed Professor at the
Department of Pharmacology at the University of Heidelberg. From 1991
to 2004 Professor Ganten was the Founding Director and President of the
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch. He also
was Director of the Department of Pharmacology at the Benjamin Franklin
Medical Center of the Free University of Berlin. From 2004 to 2008
Professor Ganten was Chief Executive Officer at the “Charité –Universitätsmedizin Berlin”, the
joint medical faculty of the Free University and Humboldt University of Berlin. Since 2005
Professor Ganten is the Chairman of the Foundation Board of the Charité Foundation. Since
2009 he is also Chairman of the joint Board of Trustees of the Max Planck Institute of Colloids
and Interfaces and of the Max Planck Institute of Molecular Plant Physiology (Berlin-Potsdam),
and he is President of the World Health Summit. As a research scientist in the field of
hypertension, Professor Ganten elucidated fundamental mechanisms of the pathophysiology
and molecular biology of high blood pressure. His area of research includes the hormonal
regulation of blood pressure, especially the renin-angiotensin system, and the molecular genetics
of cardiovascular diseases and evolutionary medicine.
S unda y 1 5 May
OPENING LECTURE
ABSTRACT
The human body, its organs, cell function, biochemistry and our genes are the result and a living
archive of evolution. Many evolutionary mechanisms are now understood in detail on a molecular
and genomic basis. This opens up new vistas to a better understanding of the basis of health
and disease. In addition to asking proximate questions how a disease mechanism is best
understood, we can start investigating ultimate questions why we get sick. The gap between
evolutionary old body functions on the one hand and modern lifestyles in new urban societies
on the other hand results in diseases of civilization. Evolutionary Darwinian Medicine makes use
of these new insights for research, diagnosis, treatment and prevention of disease.
13
Sunda y 1 5 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
CLOSED MEETINGS
9:00-13:00
Hall 8
IFCC Council
8:30-17:00
Room 47
IFCC C-AQ
Co-Chairs: E. Amann, J. Gill
8:30-18:00
Room 50
IFCC SD-EC
Chair: I. Young
9:00-13:00
Room 46
IFCC C-CC
Chair: T. Ozben
9:00-17:00
Salon 19
IFCC C-RIDL
Chair: K. Ichihara
14
13:30-17:00 Hall 8
EFCC General Assembly
13:30-14:30 Salon 20
IFCC TF-HbA1c
Chair: G. John
14:30-17:00 Salon 20
HbA1c Network Laboratories
Open Meeting
Chair: C. Weykamp
15:00-17:00 Room 48
IFCC e-News
Chair: E. Delvin
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Symposium 1
HALL 1
BIOMARKERS FOR THE DIAGNOSIS OF CARDIOVASCULAR DISEASES
Chairs: I. Young (United Kingdom), A. von Eckardstein (Switzerland)
9:00
Clinical implication of high sensitive troponin testing
S. Blankenberg (Germany)
9:25 Quality specifications for troponin assays
R. Christenson (USA)
9:50 Cellular and molecular imaging
R. Choudhury (United Kingdom)
10:15 BNP and heart failure
C. Müller (Switzerland)
10:40 High sensitive cardiac troponin T in the clinical work-up of patients with stable
chest pain
A.M.A. Mingels (The Netherlands)
10:50 I-PRESERVE sub-study: Plasma collagen markers in the prediction of death and
hospitalisation in patients with heart failure and preserved ejection fraction
H.G Schneider (USA)
Monda y 1 6 May
9:00 - 11:00
Symposium 2
HALL 3
DIAGNOSTIC CHALLENGES IN LIVER DISEASE
Chairs: F. Ceriotti (Italy), B. Gouget (France)
9:00
Non-alcoholic fatty liver disease (NAFLD)
V. Ratziu (France)
9:25 Biomarkers of fibrogenesis for the diagnosis and the activity of the fibrosis
process in liver diseases
M. Vaubourdolle (France)
9:50 Hepatocellular carcinoma: Molecular pathogenesis and clinical aspects
H. Blum (Germany)
10:15 Occult hepatitis B infection: Diagnosis and significance
W. Gerlich (Germany)
10:40 Plasma levels of soluble CD30 and CD40L in pediatric patients after liver
transplantation
O. Shevchenko (Russia)
10:50 Serological markers of gastric pathology
A. Caleffi (Italy)
15
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Year in Review 1
HALL 8
C L I N I C A L C H E M I S T RY 2 0 1 0 A N D B E Y O N D : O P P O R T U N I T I E S
AND CHALLANGES FOR THE NEXT DECADE
Chairs: V. Blaton (Belgium), N. Rifai (USA)
9: 00 Next-generation sequencing of plasma DNA for molecular diagnosis
D. Lo (Hong Kong)
9:30 Drugs of abuse testing, from urine to oral fluid: Scientific and legal ramifications
M. Huestis (USA)
10:00 Laboratory and clinical implications of high-sensitivity troponin assays
F. Apple (USA)
10:30 The diagnostic proteome: Prospects for biomarker discovery and
validation in plasma
L. Anderson (USA)
Symposium 3
HALL 14/2
TUMOR MARKERS IN CANCER
Chairs: M. Neumaier (Germany), T. Zima (Czech Republic)
9:00
Circulating tumor cells and bone marrow micrometastases
K. Pantel (Germany)
9:25 Measurement and diagnostic use of Prostate–Specific Antigen (PSA)
U.H. Stenman (Finland)
9:50 Biomarkers and personalized models in oncology drug development
D. Sidransky (USA)
10:15 Proteomic approaches for novel biomarker discovery
V. Kulasingam (Canada)
10:40 KLK3 and steroid 5-alpha reductase type II (SRD5A2) gene polymorphisms might affect
clinical reliability of serum PSA measurement
C.-F. Zambon (Italy)
10:50 DNA methylation of tumor suppressor and metastasis suppressor genes in circulating
tumor cells
S. Lianidou (Greece)
16
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Monda y 1 6 May
9:00 - 11:00
PARALLEL SESSIONS
Symposium
HALL 7
e L E A R N I N G A N D D I S TA N C E E D U C AT I O N I N C L I N I C A L
C H E M I S T R Y A N D L A B O R AT O R Y M E D I C I N E
Chair: E. Jacobs (USA)
9: 00 Webinairs, steaming media, blogs and other e-communications
A. Lyon (Canada)
9:30 Labtestsonline: Transmitting laboratory medicine in the context of national and
international guidelines
M. Klouche (Germany)
10:00 IFCC experiences with distance learning
E. Jacobs (USA)
10:30 e-Learning experiences of National Societies of Clinical Chemistry and
Laboratory Medicine
P. Kocna (Czech Republic)
Symposium 4
HALL 4/5
ACUTE AND CHRONIC KIDNEY DISEASES. AN UPDATE
Chairs: N. Greenberg (USA), N. Ozer (Turkey)
9:00
Unmet clinical needs in assessing CKD
G. Jones (Australia)
9:25 Cystatin C for estimation of renal function in CKD
A. Grubb (Sweden)
9:50 Biomarkers of acute kidney injury
C. Ronco (Italy)
10:15 Dyslipidemia of chronic renal disease
O. Samuelsson (Sweden)
10:40 Pregnancy associated plasma protein-A (PAPP-A) as a mortality predictor of long-term
hemodialysis patients
M. Kalousová (Czech Republic)
10:50 An error propagation formula must be used to correctly calculate uncertainty in EGFR
D.M. Parry (Canada)
17
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Symposium
HALL 9
ROLE OF NON-MEDICAL SCIENTISTS
Chair: W. Dick (Germany)
9:00
Scientific methods in medicine
W. Bauersfeld (Germany)
9:30 The advance of the science in medicine
G. Raabe-Meyer (Germany)
10:00 Medical laboratory manager – Non-analytical work
R. Lichtinghagen (Germany)
10:30 Requirements for excellence in laboratory medicine –
A melting pot of biosciences and medicine
N. Gässler (Germany)
Simultaneous translation from German to English will be provided
Workshop 1
HALL 10
9:00-10:30
REPORTING HBA1C FOR MONITORING AND DIAGNOSIS:
T H E D E V I L ' S I N T H E D E TA I L
Chair: B. Croal (United Kingdom)
9: 00 Estimated average glucose 2 years on
E.S. Kilpatrick (United Kingdom)
9:30 Status of HbA1c measurement and goals for improvement
R. Little (USA)
10:00 EQA: HbA1c fit for the diagnosis of diabetes?
C.W. Weykamp (The Netherlands)
18
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PLENARY SESSION
MOLECULAR TUMOR DIAGNOSTICS
HALL 1
Chairs: G. Beastall (United Kingdom), K. Lackner (Germany)
11:30
The potential impact of individualized therapy approaches on pediatric
cancer clinical research: Technology validation and global access
G. H. Reaman (USA)
Gregory H. Reaman, M.D., is Chair of the Children's Oncology Group (COG) since its
inception in 2000. The COG is comprised of over 200 member institutions, dedicated to
clinical, translational, and epidemiology research in childhood cancer throughout North
America, Australia, and New Zealand.
Dr. Reaman is a Professor of Pediatrics at The George Washington University School of
Medicine and Health Sciences and a member of the Division of Hematology-Oncology at the
Children's National Medical Center in Washington, D.C., which he directed for nearly 18 years.
Dr. Reaman serves or has served on the Editorial Boards of Leukemia, Journal of Clinical Oncology, Journal
of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians
Data Query (PDQ), National Cancer Institute as well as the ASCO Cancer Foundation's (www.cancer.net).
He has served as an Associate Editor of Cancer and Leukemia and Lymphoma.
11:55
Monda y 1 6 May
11:30-12:45
Cancer gene expression: A systems biology approach to biomarker
and drug development
W. N. Keith (United Kingdom)
Nicol Keith obtained his undergraduate training in genetics at Edinburgh University before
undertaking his PhD studies at the CRUK Beatson Institute for Cancer Research in Glasgow.
After post-doctoral research in areas related to cancer drug resistance, he established his
research program in the Department of Medical Oncology at Glasgow University. In 2004 he
became Professor of Molecular Oncology at the Centre for Oncology & Applied
Pharmacology of Glasgow University. Nicol's research is focused on the development of
novel therapeutics that target cellular senescence and telomerase. The approach is based on integrating
within a bioinformatic framework a wide variety of external and in-house data sources with high content
screening. Nicol is a founder and Director of Senectus Therapeutics Ltd. a drug discovery company focused
on the development of novel therapeutics that target cellular senescence. Nicol is a member of several
national and international scientific committees and is particularly active within the International Union
Against Cancer (UICC) including chairing the UICC International Cancer Technology Transfer Fellowships
(ICRETT) & YY grants committee's which facilitate rapid international transfer of cancer research techniques
and technology and clinical management skills across the globe.
12:20
Posttranslational modifications in tumor diagnosis
C. Wagener (Germany)
Professor Christoph Wagener is director of the Department of Clinical Chemistry in the Center
for Diagnostic of the University Medical Center Hamburg-Eppendorf, Germany. The central
laboratories of the clinic are part of the institute. C. Wagener was Dean of the Medical Faculty
and President of the German Society of Clinical Chemistry and Laboratory Medicine.
Molecular tumor diagnostics is the main research focus of his institute. Specifically,
posttranslational modifications such as phosphorylation and glycosylation are characterized
by the use of human protein domains involved in molecular recognition.
19
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
13:30-14:30
POSTER WALKS
Poster Area
In order to encourage discussions, poster walks will be held on Monday, Tuesday, and Wednesday
from 13:30 to 14:30. The author of the selected posters is asked to be by his/her poster panel from
13:30 to 14:30. Each author will have up to three minutes to present the poster.
The chairman selected for each poster walk will guide the walk and chair the discussion.
All delegates wishing to attend poster walks must be at the first poster panel (see poster-panel code)
at 13:30.
A
ut oim m une
Aut
u ne disease
Chair: U. Sack (Germany)
Posters
0024
0028
0032
0037
0039
0043
0044
0046
0050
0051
0052
0055
0096
0098
0105
0143
0160
0162
0144
0146
0149
0152
0157
0159
0214
0219
0218
0222
0223
0238
0317
0318
0319
0323
0326
0335
C
ancer /t umor
Cancer
u mor ma rkers
Chair: C. Wagener (Germany)
Posters
0069
0083
0084
0085
0088
0092
C
ancer /t umor
Cancer
u mor ma rkers
Chair: M. Kiehntopf (Germany)
Posters
0103
0116
0118
0125
0128
0142
C
ar diovas
c ula r dis
ease
Car
diovascular
disease
Chair: A. von Eckardstein (Switzerland)
Posters
0176
0180
0194
0196
0197
0210
C
Crr it ical care /eme rge ncy medici n e
Chair: H. van Pelt (The Netherlands)
Posters
0309
0310
0311
0313
0314
0315
D
iabet es me llitus a nd me taboli
Diabet
tabo l i c s y n d r o m e
Chair: T. Zima (Czech Republic)
Posters
0349
0352
0353
20
0355
0358
0361
0375
0376
0377
0380
0386
0398
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Posters
0437
0444
0445
0446
0450
0454
0459
0463
0470
0488
0492
0496
0547
0550
0566
0570
0575
0588
Haem
gy
H aem at olo
ology
Chair: R. Sierra Amor (Mexico)
Posters
0521
0523
0528
0536
0538
0543
Inf ect ious diseases
nd c h r o n i c )
dis e a s e s (acute
(a c ute a
and
Chair: C. Knabbe (Germany)
Posters
0648
0651
0655
0656
0660
0667
0668
0672
0673
0675
0676
0692
0778
0779
0786
0787
0795
0796
0914
0915
0918
0921
0922
0923
Liver and gastrointestina l dis e a s e s
Chair: F. Ceriotti (Italy)
Posters
0761
0762
0765
0771
0773
0776
M o n d ay 16 May
Endocr inology
ino logy
Chair: P. Carayon (France)
Pat ient and
an d labora tory mana gem e n t
Chair: R. Lichtinghagen (Germany)
Posters
0895
0897
0901
0902
0909
0911
Toxicology,
Toxicolog y, ins trume nta tion an d m e th o d s , m e ta b o l o m i c s
Chair: K. Kappert (Germany)
Posters
1156
1157
1163
1168
1170
1171
1172
1182
1183
1184
1185
1190
1257
1258
1260
1275
1292
1297
M iscellaneous
Chair: P. Sinha (Austria)
Posters
1242
1243
1247
1250
1254
1256
21
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
13:00 - 14:00
INDUSTRY-SPONSORED WORKSHOPS
HALL 8
TESTING FOR VITAMIN D DEFICIENCY: DEFINING AT-RISK
POPULATIONS
13:00 Testing for vitamin D deficiency: Defining at-risk populations
To be defined
HALL 14.2
CLINICAL AND ECONOMIC ADVANCES IN PROSTATE CANCER
DIAGNOSIS
Chair: A. Semjonow (Germany)
13:00 Prostate cancer detection: The patient’s view
V. Griesser (Switzerland)
13:20 Improving PSA – based prostate cancer detection with the Prostate
Health Index (phi)
C. Stephan (Germany)
13:40 Quantifying the economic value of phi
J. Minken (USA)
HALL 7
IMPORTANCE OF BIOMARKERS IN OPTIMISING THE TREATMENT OF
PATIENTS WITH HEART AND KIDNEY DISEASE
Chair: P. Venge (Sweden)
13:00 Introduction
P. Venge (Sweden)
13:10 ARCHITECT sensitive Troponin and clinical outcome in patients with
suspected acute coronary syndrome
N. Mills (United Kingdom); S. Walker (United Kingdom)
13:34 NGAL for the early identification of renal complications in the
Emergency Department
K. Schmidt-Ott (Germany)
22
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 4/5
TRUST BUT VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS
Chair: O. Hauss (Germany)
13:00 Trust but verify: How to evaluate haematology systems
S.J. Machin (United Kingdom)
HALL 9
THE VALUE OF IMPROVED WORKFLOW SOLUTIONS
Chair: M. Plebani (Italy)
13:00 Impacting Laboratory Workflow with Adaptable Design
T. Galloway (USA)
13:30 A User’s Experience
J. Bruemmer (Germany)
HALL 10
IMPACT OF NEW OMICS-PLATFORMS ON BIOMARKER DISCOVERY AND
APPLICATIONS
Monda y 1 6 May
13:00 - 14:00
Chair: K. Bindseil (Germany)
13:00 Glycanmicroarrays as Diagnostic Tool
P.H. Seeberger (Germany)
13:20 Unbiased and targeted Metabolite Profiling Platforms for Biomarker Discovery and
Validation
L. Willmitzer (Germany)
13:40 Autonomous Biosensors - Technologies that help to bring Biomarkers to the Patient
F.F. Bier (Germany)
23
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:15 - 15:15
INDUSTRY-SPONSORED WORKSHOPS
HALL 14.2
THE CLINICAL UTILITY OF MULTIPLEX BIOCHIPS FOR THE DETECTION
OF MULTIPLE STI’S AND RESPIRATORY PATHOGENS
Chair: P.V. Coyle (United Kingdom)
14:15 The clinical and practical implications of 10-plex Sexually Transmitted
Infection (STI) biochip array
P.V. Coyle (United Kingdom)
14:45 Ability of a multiplex biochip array to simultaneously detect up to 8
bacterial respiratory pathogens in a clinical setting
M. Diggle (United Kingdom)
HALL 4/5
SEDIMAX: RECENT AND SIGNIFICANT ADVANCES IN AUTOMATED
URINE SEDIMENT EXAMINATION
Chair: G.B.Fogazzi (Italy)
14:15 New features of sediMAX technology
G.Bayer (Hungary)
14:35 Can significant bacteriuria be detected by sediMAX ?
R.Falbo (Italy)
14:55 The identification by sediMAX of the clinically relevant urine sediment particles
G.B.Fogazzi (Italy)
24
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Symposium 5
HALL 1
FROM BENCH TO BEDSIDE IN AUTOIMMUNITY
Chairs: F. Alvarez Menédez (Spain), U. Sack (Germany)
14:30 Antiphospholipid syndrome: Pathogenesis
T. Koike (Japan)
14:55 Novel strategies for the treatment of rheumatoid arthritis
S. Gay (Switzerland)
15:20 The many challenges of autoantibody testing
J. Sheldon (United Kingdom)
15:45 New clinical aspects in rheumatoid arthritis - Guideline based management
J.S. Smolen (Austria)
16:10 Profiling of antiphospholipid antibodies – Association with cerebrovascular
events in antiphospholipid syndrome
D. Roggenbuck (Germany)
16:20 The Anti-CCP antibodies correlated with rheumatoid factor, erythrocyte sedimentation
rate and disease activity index in rheumatoid arthritis
IP. Guzmán-Guzmán (Mexico)
Monda y 1 6 May
14:30 - 16:30
Symposium 6
HALL 3
DIABETES MELLITUS
Chairs: A. Gronowski (USA), E. Schleicher (Germany)
14:30 IFCC standardised HbA1c: Should the world be as one?
W. G. John (United Kingdom)
14:55 Genetics of type 2 diabetes - Are we getting any closer?
A. Rosengren (Sweden)
15:20 HbA1c in the diagnosis of diabetes: Opportunities and problems
D. Sacks USA)
15:45 Molecular and biochemical mechanisms of diabetic complications
P. Gillery (France)
16:10 Hemeoxygenase-1 and its metabolic role in the liver
E. Einwallner (Austria)
16:20 Urinary 8-hydroxydeoxyguanosine as a biomarker of microangiopathic complications
in Type 2 diabetic patients
S.H.Atef (Egypt)
25
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:30 - 16:30
PARALLEL SESSIONS
Workshop 2
HALL 8
14:30-16:00
E M E R G I N G I N F E C T I O N S AT A F C B C O U N T R I E S
Chairs: W. ElGarf (Egypt)
14:30 Antimicrobial resistance:
An emerging public health problem
Z. Hallaj (Egypt)
15:00 Malaria: A global threat
E.T. Khalil (Sudan)
15:30 Tuberculosis: Persisting problem in Arab countries
G. Shannan (Syria)
Symposium
HALL 7
HOW TO ASSESS THE CLINICAL EFFECTIVENESS OF
LABORATORY TESTS?
Chairs: A.R. Horvath (Australia), A. StJohn (Australia)
14:30 Industry and regulatory perspectives: Clinical evidence for IVDs
J. Rueda (Belgium)
15:00 Laboratory perspectives: Testing a test - phases of biomarker evaluation
A.R. Horvath (Australia)
15:30 Epidemiologic and economic perspectives: Evaluating the effectiveness and
costs of monitoring
P. Bossuyt (The Netherlands)
16:00 Clinical prespectives: Clinical effectiveness of self-monitoring oral anticoagulant
treatment
C. Heneghan (United Kingdom)
26
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Symposium
HALL 9
L A B O R AT O R Y M E D I C I N E - Q U O VA D I S ?
C O N D I T I O N S , S T R U C T U R E S A N D D E V E L O P M E N TA L T R E N D S I N
EUROPE
Chair: J. Aufenanger (Germany), M. Müller (Germany)
14:30 Concentration in German laboratory medicine – Where are we headed?
M. Müller (Germany)
15:00 Laboratory medicine as a medical discipline – Is the physician in the
laboratory (in)dispensable?
R. Klakow-Franck (Germany)
15:30 Laboratory medicine in competition – The Swiss experience
A.R. Huber (Switzerland)
16:00 France on its way to centralised laboratory diagnostics
B. Wiegel (Germany)
Simultaneous translation from German to English will be provided
Monda y 1 6 May
14:30 - 16:30
Interactive Session 1
HALL 10
14:30-16:00
P I T FA L L S I N T H E H E M O S TA S I O L O G I C D I A G N O S T I C S :
CLINICAL CASES
Chair: A. Griesmacher (Austria)
14:30 Current aspects and future trends in the analysis of blood coagulation
K.T. Preissner (Germany)
14:52 New anticoagulants and routine coagulation tests
A. Haushofer (Austria)
15:14 Two puzzling cases
B. Lämmle (Switzerland)
15.36 General case report
G. Weigel (Austria)
A voting system will be provided.
This session will allow delegates to interact with the speaker and make the session an active
one!
27
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
15:30 - 16:30
INDUSTRY-SPONSORED WORKSHOPS
HALL 14.2
ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA
IN EUROPE
How to face European Healthcare and Diagnostics Challenges with
process solutions that maximize clinical laboratory cost efficiencies
Chair: M.Naraghi (Germany)
15:30 Introduction and welcome
E. Hanna
15:35 Healthcare economics challenges in diagnostics
M.Naraghi (Germany)
15:55 Implementation of lean process solutions to improve Clin Lab cost efficiencies
A. Lusack (United Kingdom)
HALL 4/5
WORKFLOW OPTIMISATION BY FRONT AND BACK END AUTOMATION IN
THE DIAGNOSTIC LABORATORY
Chair: L. Binder (Germany)
15:30 Company presentation and product portfolio for
laboratory automation
R. Rest (Germany)
15:40 Front end automation at a university laboratory
L. Binder (Germany)
16:05 Automation at a large US reference laboratory
C. Hawker (USA)
28
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 8
THERAPEUTIC DRUG MONITORING IN CLINICAL DIAGNOSTICSFROM RESEARCH TO ROUTINE
Chair: C. Halter (Germany)
16:45 Analytical aspects in therapeutic drug monitoring of immunosuppressant drugs
S. Bauer (Germany)
17:15 One TDM-analysis that detects them all: The MassTox® TDM Series
C. Halter (Germany)
HALL 14.2
PERSONALISED THERAPIES FOR CHRONIC HEPATITIS B AND C:
THE LEADING ROLE OF VIROLOGICAL MARKERS
Chair: A. Stief (Germany)
Monda y 1 6 May
16:45 - 17:45
16:45 Real-time PCR based viral load assay and the
increasing complexity of HCV patients management
S. Sarrazin (Germany)
17:15 Molecular and serological HBV markers as drivers of
individualized patient's care
M. Brunetto (Italy)
29
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
16:45 - 17:45
INDUSTRY-SPONSORED WORKSHOPS
HALL 7
OVARIAN CANCER BIOMARKERS IN THE CLINICAL CONTEXT –
STRATIFICATION AND MONITORING
Chair: R. Molina (Spain)
16:45 View of an oncologist – The need to stratify
ovarian cancer patients to obtain optimal outcomes
J. Sehouli (Germany)
17:05 Diagnostic value of HE4, CA125 and the ROMA Index in ovarian cancer patients from a
tertiary center
E. Høgdall (Denmark)
17:25 The Role of CA125 in ovarian cancer follow-up
C. Marth (Austria)
HALL 4/5
HbA1c: NEW BREAKTHROUGH TECHNOLOGY FOR LABORATORIES
FACING A CHANGE OF PARADIGM
Chair: L. Thomas (Germany)
16:45 HbA1c change of paradigm
A. Mosca (Italy)
17:05 Current HbA1c techniques: what is really being measured
A. Mosca (Italy)
17:25 Next generation of separation method for HbA1c:
First evaluation of the CAPILLARYSTM 2 Flex Piercing HbA1c
P. Gillery (France)
30
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 9
ZENTRALLABOR VS. VERBUNDLABOR
Chairs: J. Kuhn (Germany); K. Richarz (Germany)
HALL 10
USING ACTIVE B12 TO DIAGNOSE VITAMIN B12 DEFICIENCY
Chair: J. Scott (Ireland)
16:45 The diagnostic accuracy of Active B12 (holotranscobalamin)
J. Scott (Ireland)
17:15 Outcomes of a multi-centre study and experience with introducing
and running Active B12 in the clinical chemistry lab
J. Lindemans (The Netherlands)
Monda y 1 6 May
16:45 - 17:45
31
Monda y 1 6 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
CLOSED MEETINGS
8:00-11:00
Room 42
IFCC WG-IANT
Chair. M. Blanes Gonzales
12.00-14.00 Room 45
Analytical harmonization EFCC/AACC
Chair: S. Sandberg
Room 44
8:00-11:00
APFCB Executive Board
14:30-17:30 Room 42
DGKL WG LC-MS/MS in Laboratory
Chair: M. Vogeser
8:00-9:00
Room 45
IFCC WG-BMS
Chair: S. Vasikaran
14:30-17:30 Room 44
EC4 Register Commission
9:00-11:00
Room 48
EFCC C-P and EC4 Foundation Board
Chair: S. Zerah
14:30-17:30 Room 45
IFCC C-CLM
Chair: E. Frank
8:00-11:00
Room 49
EFCC WG-BV
Chair: B. Bartlet
14:30-17:30 Room 48
EFCC C-S
Chair: S. Sandberg
8:00-11:00
Room 13/14
IFCC TF-PG
Chair: R. van Schaik
14:30-17:30 Room 49
IFCC C-CMBC
Chair: M. Neumaier
8:00-11:00
Salon 20
IFCC C-MD
Chair: M. Pazzagli
14:30-17:30 Salon 19
IFCC C-RIDL Networking
Chair: K. Ichihara
9:00-11:00
Room 45
DQCLM
Chair: M. Thomas
14:30-17:30 Salon 20
IFCC C-TLM
Open Meeting
Chair: A. Kessler
9:00-11.00 / 14.30-17:30
IFCC C-PR
Chair: K. Adeli
Salon 19
9:00-11:00
IFCC WG-AETR
Open Meeting
Chair. R. Bais
11:30-14:00 Room 42
DGKL AG In/Outsourcing
32
Room 47
14:30-17:30 Room 13/14
IFCC WG-SAU and WG-GFRA
Open Meeting
Chairs: N. Greenberg, G. Miller
We Impact Life
at Every Stage
At Abbott, we deliver
products you can count
on to provide superior
patient care – across
the spectrum of health.
Discovering new and better ways
to manage health has driven our work
for more than a century. Today, our
comprehensive line of products
spans the continuum of care –
from pharmaceutical therapies and
nutritional products to diagnostics
and surgical devices – addressing
important health needs from infancy
to the golden years, and in more
ways than ever.
We strive to earn your continued
trust by delivering high-quality, reliable
products backed by leading-edge
science and expertise across a range
of health care specialties.
AD0061EU2011
We deliver on our promises by focusing
on what matters most: innovative care
and a desire to make a meaningful
difference in all that we do.
Anesthesia
Cardiovascular
Hematology
Metabolics
Nutrition
Point of Care
Vascular
Animal Health
Diabetes Care
Immunology
Molecular
Oncology
Renal Care
Virology
Anti-Infectives
Diagnostics
Medical Optics
Neuroscience
Pain Management
Respiratory
Tu e s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Symposium 7
HALL 1
PHARMACOGENETICS AND PHARMACOGENOMICS
Chairs: U. Tuma (Brazil), R. van Schaik (The Netherlands)
9:00
Pharmacogenetics in the treatment of psychiatric diseases
C. Hiemke (Germany)
9:25 Pharmacogenetic predictors of drug induced liver injury
M. Pirmohamed (United Kingdom)
9:50 The rapidly evolving state of the art in clinical pharmacogenetic applications
M. Linder (USA)
10:15 Pharmacogenetics of anti-cancer therapy
R. van Schaik (the Netherlands)
10:40 Reduced overall survival of CYP2C19 *2/*2 homozygotes after myeloablative
hematopoietic stem cell transplantation
P. Jarolim (USA)
10.50 VKORC1, CYP2C9 AND CYP4F2 genetic based algorithm for warfarin dosing.
Preliminary results of a prospective Italian study
C.-F. Zambon (Italy)
Ye a r i n R e v i e w 2
HALL 3
ADVANCES IN CLINICAL CHEMISTRY IN THE FIELD OF NEPHROLOGY
AND ENDOCRINOLOGY
Chairs: G. Benga (Romania), J. Delanghe (Belgium)
9:00
New markers for acute kidney injury
C. Ronco (Italy)
9:30 Beyond creatinine standardisation
J. Delanghe (Belgium)
10:00 POCT glucose measurement and its limitations
D. Bruns (USA)
10:30 The D-Lightful vitamin D for health
M.F. Holick (USA)
34
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Tue s da y 1 7 May
9:00 - 11:00
PARALLEL SESSIONS
Workshop 3
HALL 8
9:00-10:30
O X I D AT I V E S T R E S S I N D I A B E T E S M E L L I T U S
Chairs: T. Zima (Czech Republic)
9:00
Role of nrf2 and the antistress gene response in countering oxidative stress in
diabetes mellitus
P.J. Thornalley (United Kingdom)
9:30 Oxidative stress markers in diabetic complications
A. Ceriello (United Kingdom)
10:00 Oxidative stress and caloric restriction
J. Skrha (Czech Republic)
Symposium 8
HALL 14.2
INFECTIOUS DISEASES
Chairs: S. Suerbaum (Germany), R. Tauber (Germany)
9:00
Impact of genomics on molecular epidemiology of MRSA
W. Witte (Germany)
9:25 Helicobacter pylori – A global carcinogenic pathogen
S. Suerbaum (Germany)
9:50 Influenza pandemic, vaccination and pitfalls of communication
S. Becker (Germany)
10:15 The fourth dimension: Combining epidemiologic and typing data for the transition from
data to knowledge for infectious diseases
D. Harmsen (Germany)
10:40 Genotypic prediction of HIV-1 coreceptor tropism from plasma and peripheral blood
mononuclear cells in the clinical routine laboratory
J. Berg (Austria)
10.50 Leishmania: Probable genetic hybrids between species in Sudanese isolates
S.H. Hassabelgawi (Sudan)
35
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Symposium
HALL 7
BIOCHEMICAL ANALYSIS PRIZE – AWARD CEREMONY
Chair: K. Lackner (Germany), U. Walter (Germany)
9:00
Laudatory speeches
K.J. Lackner – President DGKL
J. Thiery – Vice President DGKL
9:20
Award Lectures
J.M. Rothberg (USA)
S. Pääbo (Germany)
10:40 Closing remarks
Simultaneous translation from English to German will be provided
Symposium 9
HALL 4/5
HAEMATOLOGY AND ANEMIA
Chairs: R. Sierra Amor (Mexico), J. Wesenberg (Canada)
9:00
Diagnostic of thalassemia
A. Huber (Switzerland)
9:25 How can hepcidin help us in the diagnosis of iron disorders?
D.W. Swinkels (The Netherlands)
9:50 Hepcidin function and regulation
M. Muckenthaler (Germany)
10:15 Laboratory diagnosis of hereditary spherocytosis
M.J. King (United Kingdom)
10:40 Customizing Sysmex flags for a specific patient population using statistical methods
B.A. Stotler (USA)
10:50 JAK2 V617F promotes expression of oncostatin M in myeloproliferative neoplasms:
A potential link between abnormal JAK-signaling and bone marrow microenvironment
alterations
G. Hörmann (Austria)
36
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
E M D C - C M B C Symposium
HALL 9
B I O B A N K I N G A N D L A B O R AT O R Y M E D I C I N E : T W O R E S O U R C E S
F O R M O D E R N H E A LT H C A R E
Chairs: M. Neumaier (Germany)
9:00
Biobanking infrastructures: Networks for future
biomedical research and laboratory medicine
M. Neumaier (Germany)
9:30 Ethical and bio-legal aspects: Crossborder experiences in Europe
M. Kiehntopf (Germany)
10:00 Public health and biobanking – The role of public health genomics
A. Brand (The Netherlands)
10:30 The key role of biobanking for the study of complex diseases
M. Ferrari (Italy)
Workshop 4
HALL 10
U P D AT E O N C A R D I A C T R O P O N I N C L I N I C A L A N D L A B O R AT O R Y I S S U E S
Tue s da y 1 7 May
9:00 - 11:00
9:00-10:30
Chair: J. Tate (Australia)
9:00
A roadmap for cardiac troponin I standardization and traceability
D. Bunk (USA)
9:30 The round Robin study for cardiac troponin I - Progress report
J. Tate (Australia)
10:00 Clinical use of high-sensitivity troponin assays
H.A. Katus (Germany)
37
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
11:30-12:45
PLENARY SESSION
HALL 1
ADVANCES IN CLINICAL AND DIAGNOSTIC IMMUNOLOGY
Chairs: A.R. Horvath (Australia), M.M. Müller (Austria)
11:30
Chronic inflammatory bowel disease – From bench to bedside
M.F. Neurath (Germany)
Markus Neurath is an international leading scientist on the field of immunology and
endomicroscopy of the gut who was awarded with well-known research prizes for his work,
e.g. the UEGF Research Prize. His research deals with the immunologic and molecular
mechanisms in the pathogenesis of inflammatory bowel diseases and GI-cancer.
11:55
Integrative genomic analysis of T cell immunity in humans
W.N. Haining (USA)
Dr. Haining is a physician-scientist who received his undergraduate and medical degree
from Oxford University, UK. He moved to the United States in 1993 to complete medical
training in Pediatrics at Children's Hospital, Boston, and subsequently in Pediatric
Hematology/Oncology at Dana-Farber Cancer Institute. After post-doctoral research at MIT
and Dana-Farber Cancer Institute, he was appointed to the faculty as Assistant Professor
of Pediatrics in 2007 in the Department of Pediatric Oncology. Dr. Haining's research
focuses on understanding why the immune system fails in cancer and chronic viral disease.
His studies have integrated cutting edge genomics and computational biology approaches with cellular
immunology to identify the critical molecular mechanisms that impair the T cell response to HIV and tumor
cells. His work has provided novel therapeutic targets to revive defective HIV-specific T cell immunity and
have laid the groundwork for the broader understanding of the immunologic genome.
12:20
Gene-environment interaction in chronic inflammatory disease
H. Renz (Germany)
The central research area of Harald Renz is the role of the adaptive immune system in the
pathogenesis of allergy and asthma. He is internationally recognized for his work on the role
of T-cell effector subsets on initiation, progression and remodelling of chronic inflammatory
disease, particularly in bronchial asthma and atopic dermatitis. He was among the first to
demonstrate that T-cells play an important role in the development of airway hyperreactivity
in asthma and trigger the chronic inflammatory response in this condition. He pioneered the
development of disease-related animal models which mimic several important hallmarks of
the disease, including initiation, progression and remodelling. In terms of disease-initiation, he provides
important contributions to the "hygiene hypothesis". He is serving as immunological study site in several
international research consortia and proved the importance of early life events for programming of the
immune system. His work offers novel cellular and molecular explanation for the role of microbes in
preventing the development of allergic conditions even in a transgenerational manner.
38
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
POSTER WALKS
Poster Area
In order to encourage discussions, poster walks will be held on Monday, Tuesday, and Wednesday
from 13:30 to 14:30. The author of the selected posters is asked to be by his/her poster panel from
13:30 to 14:30. Each author will have up to three minutes to present the poster.
The chairman selected for each poster walk will guide the walk and chair the discussion.
All delegates wishing to attend poster walks must be at the first poster panel (see poster-panel code)
at 13:30.
A
geing
Ageing
Chair: M. Walter (Germany)
Posters
0001
0002
0003
0004
0005
0006
0007
0008
0009
0010
0035
0036
0038
0040
0042
0054
0144
0146
0149
0152
0157
0159
0493
0494
0495
0498
0501
0503
0579
0580
0582
0583
0584
0587
0617
0619
0621
0627
0629
0634
A
ut oim m une
Aut
u ne disease
Chair: J. Lopez (Malaysia)
Posters
0021
0025
0027
0030
0033
0034
Tue s da y 1 7 May
13:30-14:30
Endocr ino
logy
inology
Chair: M. Kiehntopf (Germany)
Posters
0103
0116
0118
0125
0128
0142
C
ar diovas
c ula r dis
ease
Car
diovascular
disease
Chair: C. Knabbe (Germany)
Posters
0449
0451
0452
0453
0464
0491
H
aem at ology
Haem
Chair: L. Thomas (Germany)
Posters
0520
0524
0527
0533
0560
0563
H
aem ost as
Haem
a s is
Chair: U. Walter (Germany)
Posters
0595
0597
0598
0604
0606
0611
39
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Kidney
K idney dise
dis e a s e
Chair: F. H. Perschel (Germany)
Posters
0696
0700
0703
0705
0713
0718
0724
0730
0739
0741
0745
0755
0815
0817
0821
0825
0831
0834
M olecular dia
gnostics
diagnos
tic s
Chair: K. Psarra (Greece)
Posters
0798
0802
0805
0806
0809
0814
Neur
a l dis
e a s e s (acute
nd chronic)
N eur ologic
ological
diseases(a
c ute a
an
Chair: G. Sypniewska (Poland)
Posters
0836
0839
0841
0844
0845
0846
0847
0850
0855
0858
0859
0900
0906
0907
0910
0917
0920
Pat ient and
an d labora tory mana gem e n t
Chair: P. Sinha (Austria)
Posters
0890
0891
0892
0896
0898
0899
Phar m acogene
aco gene tic s /pharmacogen o m i c s
Chair: E. Wieland (Germany)
Posters
0925
0926
0928
0929
0930
1014
1015
1025
1028
1037
1038
1063
1064
1069
1072
1074
1225
1226
1228
1231
1234
1236
1063
1064
1069
1072
1074
Vit am ins
Chair: R. Bais (Australia)
Posters
1215
1216
1217
1218
1219
1222
Q
ualit y assessme nt, s tandardiz a ti o n
Qualit
Chair: W. Herrmann (Germany)
Posters
1014
1015
1025
40
1028
1037
1038
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 8
INCREMENTAL VALUE OF H-FABP IN AN ERA OF HIGHLY SENSITIVE
TROPONINS
Chair: R. Body (United Kingdom)
13:00 The diagnostic utility of heart-type fatty acid
binding protein in patients with acute coronary syndrome
J. Barth (United Kingdom)
13:30 Heart-fatty acid binding-protein may enable immediate exclusion of
acute myocardial infarction in the emergency department
R. Body (United Kingdom)
HALL 14.2
FROM CLINICAL CHEMISTRY TO MOLECULAR DIAGNOSTICS: INNOVATIVE
SOLUTIONS FOR LABORATORY AUTOMATION AND ORGANISATION
Chair: J. Wood (United Kingdom)
13:00 Reaching optimal efficiency in a high volume laboratory
D. Münstermann (Germany)
13:20 AU5800: The new ultra high throughput chemistry analyser –
First experience
T. von Schrenck (Germany)
13:40 UniCel DxN, the next generation in clinical molecular diagnostics automation
M. Topham (USA)
Tue s da y 1 7 May
13:00 - 14:00
HALL 7
LABORATORY DIAGNOSIS OF HEPATITIS C – WHAT ARE LOOKING FOR?
Chair: A. Vockel (Germany)
13:00 Hepatitis C infections –
A hidden, but no “occult” disease
J. Izopet (France)
13:30 HCV Antigen –
An effective marker to improve HCV diagnostics?
P. Holder (Ireland)
41
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
13:00 - 14:00
INDUSTRY-SPONSORED WORKSHOPS
HALL 4/5
TRUST BUT VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS
Chair: O. Hauss (Germany)
13:00 Trust but verify: How to evaluate haematology systems
S.J. Machin (United Kingdom)
HALL 9
FOCUS ON NEW DIAGNOSTIC STRATEGIES IN AUTOIMMUNITY
Chair: I. Abreu (Portugal), N. Bizzaro (Italy)
13:00 A simplified diagnostic algorithm for celiac disease
E.Tonutti (Italy)
13:20 Clinical and diagnostic significance of anti-ENA antibodies
J.Jimenez Alonso (Spain)
13:40 A new multiparametric chemiluminescent assay for the screening of ENA antibodies
N.Bizzaro (Italy)
HALL 10
ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA
IN EUROPE
Innovative technological platforms and high quality services to enhance
productivity in increasingly complex Lab structures
Chair: A.Lusack (United Kingdom)
13:00 Introduction and Welcome
A.Lusack (United Kingdom)
13:05 Implementation of innovative technological platforms in increasingly complex
laboratory structures
H.Baum (Germany)
13:30 e-connectivity and remote monitoring center: A user’s perspective
P.Howell (United Kingdom)
42
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 14.2
NEW HORIZONS IN CELLULAR ANALYSIS
Chair: R. Simon (Switzerland)
14:15 Volume, conductivity and scatter properties of leukocytes
(VCS Technology) is a highly sensitive and specific predictor
of blood culture proven neonatal sepsis
M. Bhargava (India)
14:35 Is that the microscope WBC differential count has a future
in a hematology lab: the benefits of HematoFlowTM concept
O. Pradier (Belgium)
14:55 Anemia – New insights
R. Simon (Switzerland)
HALL 4/5
DIAGNOSTIC AND CLINICAL IMPORTANCE OF MEASURING VITAMIN D
TOTAL
Tue s da y 1 7 May
14:15 - 15:15
Chair: P. Sibley (United Kongdom)
14:15 Technical and Clinical Aspects
M. Vogeser (Germany)
14:40 Multicenter Study of a New Assay on Centaur XP
W. Fraser (United Kingdom)
43
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:30 - 16:30
PARALLEL SESSIONS
Symposium 10
HALL 1
D I A G N O S T I C U S E A N D VA L U E O F F U N C T I O N T E S T I N
ENDOCRINOLOGY
Chairs: P. Carayon (France), L. Thienpont (Belgium)
14:30 Molecular genetic work up for thyroid and parathyroid diseases
F. Raue (Germany)
14:55 Diagnostic workup of primary aldosteronism
M. Stowasser (Australia)
15:20 Vitamin D: Clinical relevance, analytical issues
E. Cavalier (Belgium)
15:45 Hormonal changes after gastric surgery and obesity interventions
C. Le Roux (United Kingdom)
16:10 Genetic determinants of serum testosterone concentrations in men
R. Haring (Germany)
16:20 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas
correlates with tumor size
H. Butz (Hungary)
S y m p o s i u m 11
HALL 3
POINT OF CARE TESTING - PRACTICAL ASPECTS
Chairs: M. Klouche (Germany), K. Pulkki (Finland)
14:30 Management of POCT testing program in a teaching hospital
D. Rogic (Croatia)
14:55 Update on current and developing POC applications with a global and emerging
country focus
B. Goldsmith (USA)
15:20 The operator is key in delivering quality in POC
I. Watson (United Kingdom)
15:45 Designing a Quality POCT Program using CLSI documents
L.A. Wyer (USA)
16:10 Effect of marked fluctuations in haematocrit on point of care blood glucose systems
G. Creed (United Kingdom)
16:20 Impact of analytical performance of point of care (POCT) blood glucose meters on
application of a ´tight glycaemic control´ (TGC) protocol in an intensive care unit
setting
M. Ryan (United Kingdom)
44
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Workshop 5
HALL 8
14:30-16:00
L E S S O N S F R O M T H E A S I A N - PA C I F I C M U LT I C E N T E R
R E F E R E N C E I N T E R VA L S T U D Y
Chairs: K. Ichihara (Japan)
14:30 Study design: Strategy for collaboration in the definition of
reference intervals
K. Ichihara (Japan)
15:00 Statistical considerations in the generation of reference intervals
J. Boyd (USA)
15:30 Obtaining reference intervals traceable to reference measurement systems
M. Panteghini (Italy)
Symposium
HALL 7
QUALITY MANAGEMENT ACCORDING TO THE GERMAN
R I L I B A E K : A N I N T E R N AT I O N A L P E R S P E C T I V E
Tue s da y 1 7 May
14:30 - 16:30
Chair: W. Vogt (Germany), B. Wiegel (Germany)
14:30 German Medical Associations Directive for Quality Assurance
for Medical Laboratory tests, history and last issues
W. Vogt (Germany)
15:00 Quality management and quality assurance in Italian medical laboratories
M. Ogriseg (Italy)
15:30 Quality management and quality assurance in Austrian medical laboratories
M. Hubmann (Austria)
16:00 Root mean square of measurement deviation: a new approach in German Medical
Associations Directive for Quality Assurance for Medical Laboratory tests
R. Macdonald (Germany)
Simultaneous translation from German to English will be provided
45
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:30 - 16:30
PARALLEL SESSIONS
Symposium
HALL 9
ACCREDITATION SHOULD BE FOCUSSED ON MORE THAN WELL
ORGANIZED EXAMINATIONS WITH THE LABORATORY
Chairs: C. Giroud (France), R. Jansen (the Netherlands)
14:30 IVD Directive 98/79/CE in relation to ISO 15189
J.C. Libeer (Belgium)
15:00 Influence of pre-examination aspects on result´s validity –
Are ISO 15189 requirements sufficient and clear?
L. Sprongl (Czech Republic)
15:30 ISO 15189: Coverage of validation of results and post-examination aspects:
Is this sufficient?
S. Zerah (France)
16:00 The specific roles of assessors during accreditation and beyond
W. Huisman (The Netherlands)
Workshop 6
HALL 10
14:30-16:00
T H E 2 0 0 9 I N F L U E N Z A PA N D E M I C - L E S S O N S L E A R N E D
Chair: M. Pilonetto (Brazil)
14:30 The 2009 influenza pandemic - The experience in the southern hemisphere
A. Kelso (Australia)
15:00 Impact of pandemic A/H1N1 virus mutations on drug resistance and virulence
G. Boivin (Canada)
15:30 The role of pathogenic immune complexes in severe disease caused by
pandemic influenza
F.P. Polack (Argentina)
46
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 14.2
NEXT GENERATION IN CARDIAC BIOMARKERS: LABORATORY
MEDICINE'S CONTRIBUTION TO INDIVIDUALIZED TREATMENT IN ACS
AND HEART FAILURE
Chair: S. Rougale (France)
15:30 Troponin T high sensitive : Applying the guidelines to hospital's daily life
H. Katus (Germany)
15:50 Future calls : Can GDF 15 be added value to ACS treatment?
K.C. Wollert (Germany)
16:10 NT-pro BNP guided heart failure therapy
J. Januzzi (USA)
HALL 4/5
THE CLINICAL UTILITY OF REFLEX URINE CULTURES BASED ON
URINALYSIS AND AUTOMATED URINE MICROSCOPY USING THE IQ200
WORKSTATION
Tue s da y 1 7 May
15:30 - 16:30
15:30 The clinical utility of reflex urine cultures based on urinalysis and automated urine
microscopy using the IQ200 workstation
S. Riedel (USA)
47
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
16:45 - 17:45
INDUSTRY-SPONSORED WORKSHOPS
HALL 8
THE “LEAN” ALTERNATIVE
Chair: S. Rougale (France)
16:45 Lean principles and applications to healthcare
M. Chomyn (Germany)
17:15 Practical applications of lean in UK hospital laboratory
M. Fottles (Germany)
HALL 14.2
EFFICIENT LAB ORGANIZATION FROM PRE- TO POST ANALYTIC
Chair: A. Steif (Germany)
16:45 Overview of Roche Cobas Solutions
C. Brown (Switzerland)
17:05 Optimizing a University Lab
U. Steigerwald (Germany)
17:25 The evolution of a hands-on towards a hands-free laboratory
F. Winnock (Belgium)
HALL 7
AUTOMATION TO ENSURE YOUR LAB’S EFFICIENCY
Chair: G.I. McCurdy (Germany)
16:45 An overwiew of the benefits of an automated
inventory system (RMS)
M. Orth (Germany)
17:15 The implementation and adoption of a Total Laboratory
Automation System (APS)
M. Nybo (Denmark)
48
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 4/5
COUNTING THE COST OF THE PREANALYTICAL PHASE
Chair: V. Palicka (Czech Republic), M. Plebani (Italy)
16:45 The impact of preanalytical errors on
patients’ treatment
G. Lippi (Italy)
17:05 Understanding the cost of the preanalytical phase in an
outpatient setting
G. Soffiati (Italy)
17:25 Discovering the opportunity cost of preanalytical errors
M. Nauck (Germany)
HALL 9
NEW HIGH-PERFORMANCE ASSAYS FOR THE DETERMINATION OF FREE
LIGHT CHAINS KAPPA AND LAMBDA – ADDING CONSISTENCY TO
MONITORING AND SCREENING OF MULTIPLE MYELOMA
Chair: C. Pruemper (Germany)
Tue s da y 1 7 May
16:45 - 17:45
16:45 Improving determination of FLC Kappa and Lambda by use of Monoclonal Antibodies
H. te Velthuis (The Netherlands)
17:15 High sensitivity and specificity of New Nephelometric Assays for FLC Kappa and
Lambda in Clinical Practice
R. Hoedemakers (The Netherlands)
HALL 10
CLINICAL MSMS – NEW DEVELOPMENTS IN TODAY’S LABORATORY
Chair: A. Cohen (Denmark)
16:45 Mass spectrometry for routine analysis of steroids
in clinical samples
A. Cohen (Denmark)
17:05 Vitamin D: There is a world beyond the bone, and how to gain a
reliable insight
H.J. Roth (Germany)
17:25 Standardization and quality of in vitro diagnostic medical devices
L. Thienpont (Belgium)
49
Tue s da y 1 7 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
CLOSED MEETINGS
8:00-11:00
Room 47
IFCC WG-HbA2
Chair: R. Paleari
11:30-14:00 Room 44
ISC Worldlab Istanbul 2014
Chair. N. Ozer
Room 48
8:00-11:00
EFCC WG-TE
Chair: AR. Horvath
13:00-15:00 Room Schönefeld
DGKL Executive Committee
8:00-9:30
Salon 11/12
EFCC WG-DE
Chair: D. Gruson
Salon 11/12
9:30-11:00
EFCC C-ET and WG-CPE
Chair: E. Topic
14:00-17:00 Salon 11/12
IFCC TF-YS - Open Meeting
Chair: D. Gruson
14:30-16:00 Room 43
IFCC Corporate Members
Chair: T. Brinkmann
8:00-11:00
Room 49
IFCC C-MD
Chair: M. Pazzagli
14:30-17:00 Room 44
IFCC National Societies Editors &
Publishers
Chair: E. Delvin, E. Jacobs
9:00-10:00
Room 45
EFCC WG-TFG PA
Chair: A. Simundic
14:30-17:30 Room 45
IFCC C-RSE
Chair: F. Ceriotti
9:00-11:00
Room 44
ISAB Euromedlab Milano 2013
Chair: M. Panteghini
14:30-17:30 Room 47
IFCC C-EBLM
Chair: R. Christenson
10:00-13:00 Room 45
EFCC C-PPR
Chair: A. Wootton
14:30-17:30 Room 48
IFCC WG-SCC
Chair: A. Grubb
10:30-11:30 Room 43
Bergmeyer Conference Steering
Committee Meeting
Chair: I. Young
14:30-17:30 Room 49
EFCC WG-G
Chair: W. Oosterhuis
11:00-16:30 Room 42
DGKL Division Molecular Diagnostics
Chair: M. Neumaier
50
17:00-18:30 Room 43
DGKL Meeting Members
Incomparable performance
in Autoimmunity
The chemiluminescence-based Zenit RA analyzer meets laboratory
needs and provides the operator with:
• Extreme flexibility (up to 15 immunoassays on board; continuous access
to samples, reagents consumables and parts)
• Rapid analysis (first result within 25 minutes; throughput: 70
tests/hour)
• Full traceability (barcode reading for all reagents and samples; continuous
control of reagent levels; quality control based on Levey-Jenning &
Westgard charts)
ô-OREôWAYSôTOôTRANSFORMô
LABORATORYôWORKFLOW
ô XCEEDINGôEXPECTATIONSôFORôCAPACITYô
%
PERFORMANCEôANDôQUALITYôATô%Lô0ONIENTEô(OSPITAL
“With a workload that has doubled in five years, we needed to improve sample
management and laboratory procedures to keep pace with demand. By partnering
with Beckman Coulter, we automated 90 percent of our manual test processes,
improving our ability to provide physicians with timely and consistent results.
El Poniente Hospital is well positioned to support the region’s healthcare structure –
helping to advance the quality of medical treatment and patient care to all who
live in the area we serve.”– Dr. Cristóbal Avivar, Director of the Integrated
Biotechnology Management Area, El Poniente Hospital, El Ejido, Almeria, Spain.
Find out more about how Beckman Coulter can help you improve performance in your
laboratory at IFCC-WorldLab and EuroMedLab 2011.
ô"LOODô"ANKINGôôôô#ENTRIFUGATIONôôôô#HEMISTRYôôôô&LOWô#YTOMETRYôôôô(EMATOLOGYôôôô(EMOSTASIS
)MMUNOASSAYôôôô)NFORMATIONô3YSTEMSôôôô,ABô!UTOMATIONôôôô-OLECULARô$IAGNOSTICSôôôô2APIDô$IAGNOSTICS
© 2011 Beckman Coulter, Inc. Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc.
6ISITôUSôATô
)&##7ORLD,ABôANDô
%URO-ED,ABôô
"OOTHô.Oôô(ALLôô
BECKMANCOULTERCOM)&##
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Symposium 12
HALL 1
BIOMARKERS IN ACUTE AND CHRONIC BRAIN DISEASES
Chairs: R.N. Martins (Australia), G. Sypniewska (Poland)
9:00
Dissecting Alzheimer's disease: Is AD pathology as a cause or a consequence?
G. Casadesus (USA)
9:25 Multiple sclerosis
A.H. Cross (USA)
9:50 Identifying blood biomarkers to improve the management of stroke
W. Whiteley (United Kingdom)
10:15 S100B protein: A screening tool for the diagnosis of minor head injury
J.L. Beaudeux (France)
10:40 Evaluation of the new Marburg cerebrospinal fluid (CSF) model with
human spondylopathies
A. Dorn-Beineke (Germany)
10:50 Prostatic acid phosphatase (PAP) in neurotransmission
P.Vihko (Finland)
Ye a r i n R e v i e w 3
HALL 3
DEVELOPMENTS IN CLINICAL LABORATORY PRACTICE
We dne s da y 1 8 May
9:00 - 11:00
Chairs: M. Plebani (Italy), I. Rydén (Sweden)
9:00
Translational medicine: The case of laboratory medicine
M. Plebani (Italy)
9:30 Risk management in the pre-analytical phase
G. Lippi (Italy)
10:00 Risk analysis of the analytical testing process
J. Westgard (USA)
10:30 Reference values and beyond
F. Ceriotti (Italy)
53
Wedn e s da y 1 8 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Workshop 7
HALL 8
CLINICAL PHARMACOGENETICS
9:00-10:30
Chairs: M. Pirmohamed (United Kingdom)
9:00
CYP2D6 Genotyping to guide use of tamoxifen in breast cancer
K. Weck (USA)
9:30 Pharmacogenetics of coumarin
J. Oldenburg (USA)
10:00 Can drug induced liver injury be predicted by pharmacogenetics?
T. Szekeres (Austria)
Symposium 13
HALL 14.2
PRENATAL AND NEONATAL SCREENING
Chairs: J.J.M. Hicks (USA), K. Kohse (Germany)
9:00
Pre-eclampsia: Genetic and epigenetic aspects
C.B.M. Oudejans (The Netherlands)
9:25 An update on antenatal screening for Down's syndrome
N. Wald (United Kingdom)
9:50 Circulating cell-free fetal DNA in maternal plasma: Prospects for non-invasive
prenatal assessment of fetal aneuploidies
D. van den Boom (USA)
10:15 Recommendations in prenatal screening in the world and connections to other
diseases like thyropathy
T. Zima (Czech Republic)
10:40 Automated assays for sVEGF-R1, PlGF, Inhibin-A and PAPP-A as an aid in early
prediction of preeclampsia : preliminary results from a prospective clinical study in a
general population
V. Tsatsaris (France)
10:50 First-trimester risk calculation for trisomy 13, 18, and 21: Comparison of the screening
efficiency between two self-developed programs and astraia software
S. Sørensen (Denmark)
54
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Symposium
HALL 7
S TA N D A R D I Z AT I O N I N M O L E C U L A R D I A G N O S T I C S
Chairs: I. Young (United Kingdom)
9:00
The need for standardization in molecular diagnostics
M. Pazzagli (Italy)
9:30 Standardization in molecular diagnostics: Definitions and uses of
nucleic acid reference materials
D. Payne (USA)
10:00 The IFCC network of molecular diagnostic centres
F. Rousseau (Canada)
10:30 The pharmacogenetics reference laboratory: An IFCC molecular diagnostic
center in action
R. van Schaik (The Netherlands)
Symposium 14
HALL 4/5
ALLERGY DIAGNOSTICS
Chairs: C.W.K. Lam (Hong Kong), J. Lopez (Malaysia)
9:00
Emerging concepts in individualized therapy of atopic dermatitis
T. Bieber (Germany)
9:25 Component-based diagnostics - recombinant allergens as diagnostic tools
R. Valenta (Austria)
9:50 Carbohydrate allergens
T.A.E. Platts-Mills (USA)
10:15 The role of in vitro tests in the diagnosis of food allergy
T. Werfel (Germany)
10:40 Components-array technology diagnostic, a step forward in the study of the
sensitization profile of allergic patients
J.M. Acedo (Spain)
10:50 RecoveryELISA - A newly developed immunoassay for measurement of therapeutic
antibodies (MAb) and the target antigen during antibody therapy
G. Becher (Germany)
We dne s da y 1 8 May
9:00 - 11:00
55
Wedn e s da y 1 8 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Symposium
HALL 9
DEVELOPMENT OF A TRANSCRIPTOMIC, PROTEOMIC AND
M E TA B O L O M I C D ATA B A S E F O R H U M A N B L O O D C E L L S
Chair: G. Schmitz (Germany), C. Wagener (Germany)
9:00
Problems and solutions for consolidated blood cell proteome analysis
H. E. Meyer (Germany)
9:30 A data storage and retrieval system for across-Omics data integration
in eukaryotic systems
K. Helsen (Belgium)
10:00 The proteome of resting and activated platelets
R. Zahedi (Germany)
10:30 Transcriptomics, proteomics and lipidomics from megakaryopoesis
to platelet senescence
G. Schmitz (Germany)
Simultaneous translation from German to English will be provided
Workshop 8
HALL 10
9:00-10:30
MOLECULAR DIAGNOSIS OF INFECTION
Chair: M. Tavora Mira (Brazil)
9:00
Molecular diagnosis of tuberculosis
E. Domann (Germany)
9:30 Challenges of molecular diagnosis - The leprosy model
V. Vissa (USA)
10:00 Molecular diagnosis of viral infections: Arboviruses and
rodent-borne viruses
L. Moraes Figueiredo (Brazil)
56
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PLENARY SESSION
HALL 1
THE BRAIN: BIOLOGICAL AND CEREBRAL DISEASES
Chairs: R. Tauber (Germany), I. Young (United Kingdom)
11:30
Alzheimer's disease: From molecular pathology to diagnosis and
treatment approaches
R.N. Martins (Australia)
Professor Ralph Martins' career in Alzheimer's disease has spanned 25 years and resulted
in over 200 publications in mid to high impact journals. He established the McCusker
Foundation for Alzheimer's Disease Research. He brought together researchers from
Western Australian universities, hospitals and aged care providers to establish the Centre
of Excellence for Alzheimer's Disease Research of which he is director. With Professors
Colin Masters and David Ames, he was successful in obtaining a CSIRO Flagship grant to
identify early diagnostic markers of AD. He founded the Western Australian biotech company Alzhyme to
develop anti-amyloid drugs for Alzheimer's Disease. This has allowed Alzhyme to take a lead compound
from concept to successful animal trials in 4 years.
11:55
Biomarkers in multiple sclerosis
M. Comabella (Spain)
Education/Training
1990 University of Barcelona - MD Medicine
1995 Hospital Vall d’Hebron - Specialist Neurology
Scientific Training and Experience
1992 - 1995 Resident in Neurology. Hospital Vall d'Hebron, Barcelona. Spain
1996 - 1998 Research fellowship in Neuroimmunology. Harvard Medical School, Center
for Neurologic Diseases - Brigham and Women´s Hospital, Boston, US
1999 - 2001 Research and Clinical Neurologist. Hospital Vall d'Hebron
Present Position
Research and Clinical Neurologist. Deputy Director Neuroimmunology lab. Clinical Neuroimmunology
Unit. Hospital Vall d'Hebron. Barcelona, Spain
12:20
We dne s da y 1 8 May
11:30-12:45
Mechanisms of neurotoxicity and neurodegeneration in prion diseases
A. Aguzzi (Switzerland)
A. Aguzzi is professor and director of the Institute of Neuropathology at the University of
Zurich. His research career has focused entirely on prions, exploring how they damage brain
cells, why they accumulate in lymphoid organs, and how they reach the brain after entering
the body from peripheral sites. He is the Founder and Director of the Swiss National
Reference Center for Prion Diseases, and is on the Board of Governors of the Swiss Federal
School of Technology. He has developed and patented several diagnostic and therapeutic
methods in the field of transmissible spongiform encephalopathies. He is an adviser to the
British, Italian, and Swiss government on spongiform encephalopathies. Among other honors, Dr. Aguzzi
has won 2009 the Antonio-Feltrinelli Prize in Rome, as well as the medal of the European Molecular Biology Organization (EMBO).
57
Wedne s da y 1 8 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
13:30-14:30
POSTER WALKS
Poster Area
In order to encourage discussions, poster walks will be held on Monday, Tuesday, and Wednesday
from 13:30 to 14:30. The author of the selected posters is asked to be by his/her poster panel from
13:30 to 14:30. Each author will have up to three minutes to present the poster.
The chairman selected for each poster walk will guide the walk and chair the discussion.
All delegates wishing to attend poster walks must be at the first poster panel (see poster-panel code)
at 13:30.
C
ar diovas
c ula r dis
ease
Car
diovascular
disease
Chair: J. Tate (Australia)
Posters
0187
0195
0198
0200
0211
0220
0224
0246
0249
0258
0291
0302
D
iabet es mellitus and meta bo l i c s y n d r o m e
Diabet
Chair: F. H. Perschel (Germany)
Posters
0336
0338
0340
0345
0388
0399
0403
0413
0415
0417
0424
0426
0513
0514
0515
0516
0517
0519
Genet
isease
G enet ic d
dis
ease
Chair: B. Hoppe (Germany)
Posters
0507
0508
0509
0510
0511
0512
Inf ect ious diseases (acute a nd c h r o n i c )
Chair: M. Walter (Germany)
Posters
0636
0638
0640
0641
0642
0643
0646
0647
0653
0654
0677
0687
0710
0711
0714
0719
0754
0760
0775
0777
0780
0783
0785
0788
K
idney disease
Kidney
dis e a s e
Chair: N. Ozer (Turkey)
Posters
0694
0695
0702
0706
0707
0709
Liver and ga
s trointe s tinall disea
gastrointestina
dis e a s e s
Chair: B. Gouget (France)
Posters
0766
0768
0769
58
0770
0772
0774
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Posters
0835
0837
0838
0843
0848
0849
0851
0852
0853
0854
0856
0878
0879
0884
0885
0887
0888
0948
0953
0954
0956
0958
0963
0983
0985
0987
0991
1009
1011
1041
1049
1051
1055
1060
1061
Paediat r ic c linic a l c hemistry
Chair: K. Kohse (Germany)
Posters
0870
0871
0872
0873
0874
0876
Point of care te s ting
Chair: K. Pulkki (Finland)
Posters
0933
0934
0936
0937
0938
0947
Pr egnancy a nd ne ona tology
Chair: K. Tomberg (Estonia)
Posters
0974
0977
0978
0980
0981
0982
We dne s da y 1 8 May
Neur
a l dis
e a s e s (a
c ute an
N eur ologic
ological
diseases
(acute
a nd c h r o n i c )
Chair: J.-L. Beaudeux (France)
Q
ualit y assessme nt, s tandardiz a ti o n
Qualit
Chair: C.B.M. Oudejans (The Netherlands)
Posters
1019
1020
1024
1026
1035
1036
Technolog
y, ins
trume nta tion an
Technology,
instrumentation
a n d m e th o d s , m e ta b o l o m i c s
Chair: O. Wagner (Austria)
Posters
1078
1084
1090
1098
1103
1109
1117
1133
1140
1147
1149
1151
Technolog
y, ins
trume nta tion an
Technology,
instrumentation
a n d m e th o d s , m e ta b o l o m i c s
Chair: E. Wieland (Germany)
Posters
1080
1085
1100
1118
1119
1122
1127
1128
1143
1145
1146
1150
1200
1201
1203
1204
1207
1208
Tr aceabllity and s tandardizatio n
Chair: K. Ichihara (Japan)
Posters
1194
1195
1196
1197
1198
1199
59
Wedn e s da y 1 8 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
13:00 - 14:00
INDUSTRY-SPONSORED WORKSHOPS
HALL 8
THE USE OF MULTIPLEX ASSAYS FOR DETERMINING PREDISPOSITION
TO HYPERTENSION
Chair: J. Lamont (United Kingdom)
13:00 The use of multiplex assays for determining predisposition to hypertension
S. Visvikis-Siest (France)
HALL 14.2
NOVEL MARKERS IN REPRODUCTIVE ENDOCRINOLOGY
Chair: J. Barth (United Kingdom)
13:00 Anti-Müllerian hormone:
A market of ovarian reserve
R. Anderson (United Kingdom)
13:20 Anti-Müllerian hormone: Does it have a role in polycystic
ovarian syndrome?
J. Barth (United Kingdom)
13:40 New biomarker of pre-eclampsia
V. Tsatsaris (Paris)
HALL 7
VITAMIN D AND B12 – IMMUNOASSAYS IN PREVENTIVE MEDICINE
Chair: S. Lorenz
13:00 Recommendations on Vitamin D testing and an analytical
evaluation of the ARCHITECT 25-OH Vitamin D assay
E. Cavalier (Belgium)
13:30 Clinical implications and methods to detect early development
of Vitamin B 12 deficiency?
W. Hermann (Germany)
60
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 4/5
WORK AREA MANAGEMENT: THE ULTIMATE PRODUCTIVITY TOOL
Chair: O. Hauss (Germany)
13:00 Work Area Management: The ultimate productivity tool
A. Henley (United Kingdom), C. Whittington (United Kingdom)
HALL 9
F reelite TM AND H evylite TM IN MONOCLONAL GAMMOPATHIES:
IMPROVING DIAGNOSIS, MONITORING AND PROGNOSIS ASSESSMENT
Chair: M.L. Villar (Spain)
13:00 Free light chain measurement in serum – Clinical use and
laboratory handling
G. Merlini (Italy)
13:20 Why serum free light chain testing is critical in patients with
renal impairment
C. Hutchison (United Kingdom)
13:40 Heavy/Light chain antibodies for monitoring and prognostication
in patients with myeloma
A. Bradwell (United Kingdom)
We dne s da y 1 8 May
13:00 - 14:00
HALL 10
VITAMIN D DIETARY REFERENCE INTAKES: IMPLICATIONS AND
SIGNIFICANCE IN CLINICAL PRACTICE
13:00 Vitamin D dietary reference intakes: Implications and significance in clinical practice
B. Hollis (USA), S. Pilz (Austria), R. Vieth (Canada)
61
Wedn e s da y 1 8 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:15 - 15:15
INDUSTRY-SPONSORED WORKSHOPS
HALL 14.2
PERSONALISED HEALTHCARE AS A KEY DRIVER FOR PRESENT AND
FUTURE DIAGNOSTIC/THERAPEUTIC STRATEGIES
Chair: A. Stief (Germany)
14:15 Roche strategy for PHC
T. Gutjahr (Switzerland)
14:35 Biomarkers for management of breast cancer and other tumors
J. Rüschhoff (Germany)
HALL 4/5
A NEW PROSPECTIVE FOR THE AUTOMATION OF CLINICAL CHEMISTRY
TESTING
Chair: C. Kostner (Germany)
14:15 respons® 910: A multipurpose clinical chemistry system
R. Schenk (Germany)
14:35 Hands-on experience with respons® 910 during external evaluation
M.M. Stratmann (Germany)
14:55 Photometric determination of electrolytes – The alternative to ISE
S.Meyer (Germany)
62
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Symposium 15
HALL 1
N E W D E V E L O P M E N T S I N H A E M O S TA S E O L O G Y
Chairs: N. Majkic-Singh (Serbia), U. Walter (Gerrmany)
14:30 Coagulation factor XIII deficiency
L. Muszbek (Hungary)
14:55 Genetics and epidemiology of thrombophilia
F.R Rosendaal (The Netherlands)
15:20 Platelets
U. Walter (Germany)
15:45 Monitoring of anticoagulant therapy
B. Lämmle (Switzerland)
16:10 Detection of an additional, newly detected polymorphism in the factor
V gene with a heterozygous factor V Leiden genotype showing a
normal APC-resistence test result
F. Prüller (Austria)
16.20 Direct thrombin-inhibitors lead to underestimation of thrombotic risk by influencing
functional APC-resistance testing
L. Loacker (Austria)
We dne s da y 1 8 May
14:30 - 16:30
Symposium 16
HALL 3
CONTRIBUTION OF LABORATORY MEDICINE IN LEUKAEMIA
Chairs: P. Schuff-Werner (Germany), O. Zinder (Israel)
14:30 Acute myeloid leukemia: Molecular diagnostics and MRD
A. Neubauer (Germany)
14:55 Identification of prognostic subgroups in acute leukemia by novel phenotypic patterns
and MDR assay
J. Kappelmayer (Hungary)
15:20 Diagnosis of AML between morphology and next generation sequencing
T. Haferlach (Germany)
15:45 Myeloproliferative neoplasia: Diagnostic tools for classification and therapy guidance
J. Westermann (Germany)
16:10 A rapid bacterial-based bioluminescent assay for in vitro testing of chemotherapy
sensitivity
J.V. Lamont (Ireland)
16:20 Endogenous colony growth predicts for a less pronounced molecular response to
Imatinib therapy in patients with chronic myeloid leukemia
E. Einwallner (Austria)
63
Wedn e s da y 1 8 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:30 - 16:30
PARALLEL SESSIONS
Workshop 9
HALL 8
14:30-16:00
W H AT PA P E R S W I L L B E P R E F E R R E D I N T H E F U T U R E
R E L AT E D T O L A B O R AT O R Y M E D I C I N E ?
EDITORS POINT OF VIEW
Chairs: G. Picheth (Brazil)
14:30 Ethical issues involving publications
J. Delanghe (Belgium)
15:00 Position in your journal about the peer review? Is there any alternative?
M. Plebani (Italy)
15:30 Editors role in improving laboratory science
N. Rifai (USA)
Symposium
HALL 7
A SCIENTIFIC APPROACH TO THE POST-ANALYTICAL PHASE
Chairs: E. Ajzner (Hungary), D. Rogic (Croatia)
14:30 Biological variation data: the need for appraisal
of the evidence base
B. Bartlett (United Kingdom)
15:00 Reflective testing - Is there evidence that it is worthwhile and for which clinical
problems?
W. Oosterhuis (The Netherlands)
15:30 Post-analytical external quality assessment - A way to assess test requesting and
interpretation?
S. Sandberg (Norway)
16:00 Postanalytical errors in lipid & lipoprotein testing
M. Langlois (Belgium)
64
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Symposium
HALL 9
R E S E A R C H F U N D I N G B Y T H E F O U N D AT I O N O F
PAT H O B I O C H E M I S T R Y A N D M O L E C U L A R D I A G N O S T I C S O F
THE DGKL – 10 YEARS ON
Chair: K. Lackner (Germany), J. Thiery (Germany)
14:30 Immunoprofiling of the new variable immunoreceptor of neutrophils in
acute systemic inflammation
W. Kaminski (Germany)
15:00 Pathogenesis of the antiphospholipid syndrome
N. Prinz (Germany)
15:30 Role of protease signalling in vascular disease
B. Isermann (Germany)
16:00 Sphingoid bases – A new class of biomarkers?
T. Hornemann (Switzerland)
Simultaneous translation from German to English will be provided
Interactive Session
HALL 10
C H A L L A N G E S AT T H E C L I N I C A L I N T E R FA C E S
We dne s da y 1 8 May
14:30 - 16:30
Chair: B. Croal (United Kingdom)
14:30 Interpretative paradigm 1: Endocrinology case
D. Freedman (United Kingdom)
15:00 Interpretative paradigm 2: Water and electrolytes case
A.R. Horvath (Australia)
15:30 Interpretative paradigm 3: Toxicology case
M. Hallworth (United Kingdom)
16:00 Interpretative paradigm 4: Diabetes case
E. Kilpatrick (United Kingdom)
A voting system will be provided.
This session will allow delegates to interact with the speaker and make the session an active
one!
65
Wedn e s da y 1 8 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
15:30 - 16:30
INDUSTRY-SPONSORED WORKSHOPS
HALL 14.2
CURRENT AND FUTURE PERSPECTIVES IN DRUGS OF ABUSE
SCREENING; THE MULTIPLEX APPROACH
Chair: C. Johnston (United Kingdom)
15:30 The evaluation of the first meprobamate, zopiclone, zolpidem and zaleplon antibodies
using biochip multiplexing technology from Randox in plasma, serum and whole blood
J.-C. Alvarez (France)
16:00 Drugs of abuse testing in the routine laboratory; multiplex screening for urine drugs of
abuse assays
C. Johnston (United Kingdom)
HALL 4/5
TRACEABILITY AND UNCERTAINTY OF CATALYTIC ACTIVITY
MEASUREMENTS
Chair: F.-J. Gella (Spain)
15:30 Uncertainty of the primary reference systems
chemistry system
F. Canalias (Spain)
15:55 Traceability and uncertainty of the values assigned to commercial calibrators
F.-J. Gella (Spain)
16:10 Traceability and uncertainty of the patient measured values
X. Fuentes-Arderiu (Spain)
66
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
8:00-9:30
Room 47
EFCC WG-A/ISO
Chair. W. Huisman
14:30-17:30 Room 48
EFCC WG-CM
Chair. P. Laitinen
8:00-11:00
Room 48
IFCC WG-POCT
Chair. R. Tirimacco
14:30-17:30 Room 49
IFCC TF-INTLN
Chair: I. Watson
8:00-11:00
Salon 20
IFCC WG-CDT
Chair. F. Schellenberg
14:30-17:30 Salon 20
IFCC WG-CDT - Open Meeting
Chair. F. Schellenberg
9:00-11:00
Room 49
EFCC WG-CS
Chair. J. Delanghe
9:30-11:00
Room 47
EFCC WG-IVD
Chair: JC. Libeer
11:30-14:00 Room 48
DGKL - VDGH Executive Boards
We dne s da y 1 8 May
CLOSED MEETINGS
14:30-17:00 Room 47
IFCC WG-LEPS
Chair. M. Plebani
67
Thu rs da y 1 9 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Symposium 17
HALL 1
NEW STRATEGIES IN MOLECULAR DIAGNOSTIC
Chairs: C. Mannhalter (Austria), K. Psarra (Greece)
9:00
DNA melting analysis: From fundamentals to practical applications
C. T. Wittwer (USA)
9:25 Quality assurance and quality control in the routine molecular diagnostic laboratory
H. Kessler (Austria)
9:50 Next generation sequencing in leukemia diagnostics
A. Kohlmann (Germany)
10:15 High throughput qPCR expression profiling, from tissue samples to single cells
M. Kubista (Sweden)
10:40 Centrifugal microfluidic platforms for molecular diagnostics
D. Mark (Germany)
10:50 Lanthanide chelate complementation in homogeneous well-based four-plex
nucleic acid array
U. Karhunen (Finland)
Symposium 18
HALL 3
STARDARDIZATION AND QUALITY CONTROL ISSUES IN EMERGING AND
DEVELOPING COUNTRIES
Chairs: G. Shannan (Syria), V. Steenkamp (South Africa)
9:00
Analytical quality in the Latin America area
G. Migliarino (Argentina)
9:25 Quality assurance programs in Arab countries
F. Harb (Syria)
9:50 Standardization and quality control issues in emerging and developing countries
E. Frank (India)
10:15 Current status of quality management in laboratory medicine in China
S. Hong (China)
10:40 Stabilizing leukocytes enables global implementation of an external quality control
for HIV-monitoring
C. Prante (Germany)
68
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Thurs da y 1 9 May
9:00 - 11:00
PARALLEL SESSIONS
Workshop 10
HALL 8
9:00-10:30
S TA N D A R D I Z AT I O N O F C O M P L E X A N A LY T E M E A S U R E M E N T S :
THE CLINBIOTRACE PROJECT
Chairs: H. Parkes (United Kingdom)
9:00
The case of human growth hormone: measurement limitations and desirable
performance for clinical use
M. Bidlingmaier (Germany)
9:30 Making laboratory medicine results comparable: Understanding the measurements
H. Schimmel (Germany)
10:00 Novel mass spectrometry approaches to detect structural variability in clinically
useful proteins: Impact on the implementation of reference systems
G. O'Connor (United Kingdom)
Symposium 19
HALL 14.2
CURRENT CHALLANGES IN THE PEDIATRIC LABORATORY
Chairs: H. Reguengo (Portugal), K. Tomberg (Estonia)
9:00
The immature platelet fraction as a novel dynamic cellular parameter for predicting and
monitoring the course of neonatal thrombocytopenia
A. Weimann (Germany)
9:25 Laboratory markers for differential diagnosis of bacterial and viral infections in children
with fever
N. Mayansky (Russia)
9:50 Childhood metabolic syndrome: Pathophysiology and laboratory assessment
K. Adeli (Canada)
10:15 Diagnostic, prognostic and therapeutic relevance of assay of B-type natriuretic
hormone and related peptides in children with congenital heart diseases
M. Cantinotti (Italy)
10:40 Pediatric normative data on Abbott, Roche, and Ortho Clinical chemistry systems:
Instrument agreement and equivalence determination utilizing pediatric samples
A.A. Venner (Canada)
10:50 The use of procalcitonin in early diagnosis
V. Santos (Portugal)
69
Thu rs da y 1 9 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
9:00 - 11:00
PARALLEL SESSIONS
Symposium
HALL 7
S TA N D A R D I Z AT I O N O F T H E P R E - A N A LY T I C A L P H A S E F O R
BIOMARKERS
Chairs: G. Lippi (Italy), A.M. Simundic (Croatia)
9:00
Standardization and improvement of generic pre-analytical
tools and procedures for in-vitro diagnostics
U.Oelmueller (Germany)
9:30 Pre-analytical parameters impacting on tissue-based biomarkers
K. Zatloukal (Austria)
10:00 Pre-analytical aspects of the Carmague study. Adherence to the AMI and
CHF guidelines
P. Laitinen (Finland)
10:30 Evidence-based quality guidelines for the pre-analytical phase of blood samples
M. Pazzagli (Italy)
Symposium 20
HALL 4/5
VITAMIN D: MYTH OR MAGIC
Chairs: R. Bais (Australia), V. Palicka (Czech Republic)
9:00
Vitamin D requirements for health
H. Bischoff-Ferrari (Switzerland)
9:25 A new paradigm for vitamin D activity in bone: Autocrine/paracrine actions
H. Morris (Australia)
9:50 Biochemistry and metabolism of vitamin D
G. Jones (Canada)
10:15 25-Hydroxyvitamin D assays - Are they fit for purpose?
G. Carter (United Kingdom)
10:40 Vitamin D in problem oriented request panel “vague complaints”
I.C.A. Munnix (The Netherlands)
10:50 Abbott Architect 25-OH vitamin D assay compared against LC-MS/MS
J. Bailey (United Kingdom)
70
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
IFCC-WASPaLM Workshop 10
HALL 9
C H R O N I C K I D N E Y D I S E A S E - D E V E L O P I N G A N AT I O N A L
TESTING PROGRAM
Chairs: M. Oellerich (Germany)
9:00
A global clinical perspective
F. Alcantara (Brazil)
9:30 Why a national program for CKD testing?
D. Seccombe (Canada)
10:00 Key factors in successful national CKD programs
G. Jones (Australia)
W o r k s h o p 11
HALL 10
9:00-10:30
BIOMARKERS OF ACUTE AND NEURODEGENERATIVE BRAIN DAMAGES
Chairs: J.L. Beaudeaux (France)
9:00
Diagnosis values of biomarkers for Alzheimer’s disease
S. Lehmann (France)
9:30 No future for CSF Alzheimer’s disease biomarkers without standardization of
preanalytical steps
A. Perret-Liaudet (France)
10:00 Cerebrospinal fluid biomarkers for the diagnosis/prognosis of neurological diseases
I. Quadrio (France)
Thurs da y 1 9 May
9:00 - 11:00
71
Thu rs da y 1 9 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
11:30-12:45
PLENARY SESSION
HALL 1
NEW AVENUES IN LABORATORY DIAGNOSTICS
Chairs: T. Ozben (Turkey), H. Renz (Germany)
11:30
Development and clinical implementation of next generation sequencing
for multi-gene diagnostic panels
K.V Voelkerding (USA)
K.V Voelkerding received his medical degree from the University of Cincinnati College of
Medicine in 1983. He subsequently pursued postgraduate training in molecular biology and
clinical pathology. From 1990 to 2000, Dr. Voelkerding was a faculty member in the
Department of Pathology and Laboratory Medicine at the University of Wisconsin-Madison.
Currently, Dr. Voelkerding is an Associate Professor of Pathology at the University of Utah
and Medical Director for Advanced Technology and Bioinformatics at the ARUP Laboratories. Dr.
Voelkerding's presentation will cover technical and bioinformatic approaches coupled with clinical examples
of multi-gene diagnostics.
11:55
Mass Spectrometry: Its future in several disciplines of laboratory medicine
D.F. Hochstrasser (Switzerland)
D.F. Hochstrasser is the chairman of the Genetic & Laboratory Medicine Department of the
Geneva University Hospital and Vice Dean of the Faculty of Medicine, University Geneva,
Switzerland. He is also Head of the Laboratory Medicine Division of the Geneva University
Hospital, Switzerland's largest acute hospital. He still practices as a Board certified physician.
At the academic level, he is Full Professor both to Geneva's Department of Structure Biology
& Bioinformatics, Medicine Faculty and to the School of Pharmacy, Sciences Faculty. His
research focus is on the discovery of clinical biomarkers in brain, pancreas and kidney
diseases, on human toxicology and the development of proteomic & clinical chemistry related technologies.
12:20
Proteomics strategies looking into cardiovascular disease.
Disrupted signalling pathways as biomarkers
A. J.R. Heck (The Netherlands)
Since 1998 Albert Heck is Full Professor at Utrecht University at the Science Faculty in the
Netherlands. He is scientific director of The Netherlands Proteomics Centre (since 2003)
and the Bijvoet Centre for Biomolecular Research (since 2006). In 2001 he was recipient of
the Golden Medal of the Dutch Royal Chemical Society. In 2004 he received an honoree
Utrecht University “ABC”-professorship and in 2010 he was guest-professor at the ETH
Zürich. He has published more than 300 papers in internationally reviewed journals. The Heck laboratory
has a track record in proteomics and especially in the analysis of protein post-translational modifications
and quantitative proteomics. He introduced and developed TiO2 as enrichment material for the targeted
analysis of phosphopeptides. For quantitative proteomics, the group introduced metabolic stable isotope
labeling in multicellular organisms such as Drosophila and C. elegans, and stable isotope labeling by using
chemical approaches. Amongst the broad biomedical interest of the group are embryonic and adult stem
cells and chemical proteomics approaches in a cardiovascular context.
72
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
INDUSTRY-SPONSORED WORKSHOPS
HALL 8
ADDING VALUE TO LABORATORY MEDICINE
Chair: G. Beastall (United Kingdom)
13:00 Introduction of new program mission
B. Luna (USA)
13:20 Good Practices: An example of UK National Pathology Week
S. Jarvis (United Kingdom)
13:40 Good Practices: Connecting with Key Stakeholders
G. Beastall (United Kingdom)
HALL 9
LC/MS IN THE CLINICAL LABORATORY - TRANSITION FROM A
RESEARCH TOOL TO ROUTINE CLINICAL LABORATORY USE
Chair: K. Khan (United Kingdom)
13:00 Implementing LC/MS/MS for therapeutic drug monitoring A 10 year review from a routine clinical laboratory perspective
M. Vogeser (Germany)
13:30 Experiences of running a routine clinical service for 25-OH vitamin D using a semiautomated LC/MS/MS
L. Perry (United Kingdom)
Thurs da y 1 9 May
13:00 - 14:00
73
Thu rs da y 1 9 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:30 - 16:30
PARALLEL SESSIONS
Symposium 21
HALL 1
N E W T E C H N O L O G I E S I N C L I N I C A L A P P L I C AT I O N
Chairs: S. Sandberg (Norway), O. Wagner (Austria)
14:30 NMR-spectroscopy in the diagnosis of metabolic diseases
R. Wevers (The Netherlands)
14:55 Strategies for protein quantification by integrated elemental and molecular
mass spectrometry
Q. Wang (China)
15:20 Screening, identifying and quantifying small molecules by hyphenated mass
spectrometry in toxicology & drug monitoring
H. Maurer (Germany)
15:45 Recent developments in the biology and applications of plasma nucleic acids
D. Lo (China)
16:10 Quantification of blood folate forms using stable-isotope dilution ultra performance
liquid chromatography tandem mass spectrometry
S.H. Kirsch (Germany)
16:20 Lanthanide chelate complementation for highly sensitive protein detection
T. Riuttamäki (Finland)
Symposium 22
HALL 3
INTERTWINING EMERGENCY MEDICINE AND LABORATORY MEDICINE
Chairs: J. Smith (United Kingdom), H. van Pelt (The Netherlands)
14:30 Medical emergencies: What is the laboratory’s role?
D.S. Young (USA)
14:55 What should the clinical laboratory and the toxicologist-pharmacologist offer
the poisoned patient?
D.R. A. Uges (The Netherlands)
15:20 The clinical laboratory and acts of chemical or biological terrorism…
Can we be prepared?
M. D. Kellogg (USA)
15:45 Laboratory resources needed to address unanticipated disasters
C. Kosack (The Netherlands)
16:10 Diagnostic and prognostic value of soluble CD14 subtype (sCD14-ST) in emergency
patients with early sepsis using the new assay PATHFAST Presepsin
E. Spanuth (Germany)
16:20 Usefulness of urinary biomarker NGAL in the management of renal replacement
therapy (RRT, hemofiltration)
O. Stanger (Austria)
74
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
PARALLEL SESSIONS
Workshop 12
HALL 8
14:30-16:00
J O I N T S E S S I O N W I T H I AT D M C T - T R E N D S I N T H E R A P E U T I C
DRUG MONITORING: PERSONALIZED IMMUNOSUPPRESSION
Chairs: E. Wieland (Germany)
14:30 TDM of immunosuppressants: Current practice and guidelines
T. van Gelder (The Netherlands)
15:00 Use of endogenous biomarkers to achieve personalized immunosuppression in
transplant recipients
M. Oellerich (Germany)
15:30 Impact of pharmacogenetics to optimize immunosuppressive therapy
I. MacPhee (United Kingdom)
Symposium
HALL 7
TRACEABILITY, STANDARDIZATION, HARMONIZATION: CONCEPTS AND
IMPLEMENTATION
Chairs: P. Gillery (France)
Thurs da y 1 9 May
14:30 - 16:30
14:30 Traceability in laboratory medicine: A review of the
international activities
A. Kessler (Germany)
15:00 Standardization versus harmonization
L. Siekmann (Germany)
15:30 Traceability, standardization, harmonization: Concepts and implementation for
heterogeneous analytes
L. Thienpont (Belgium)
16:00 Implementation of standardization in clinical practice: Not always an easy task
M. Panteghini (Italy)
75
Thu rs da y 1 9 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
14:30 - 16:30
PARALLEL SESSIONS
Workshop 13
HALL 9
14:30-16:00
V I TA M I N D E F I C I E N C Y I N E L D E R LY P E O P L E : D I A G N O S I S ,
P R E V E N T I O N A N D E F F E C T O N A G E - R E L AT E D D I S E A S E S
Chairs: W. Hermann (Germany)
14:30 B-Vitamins and neurodegeneration
R. Obeid (Germany)
15:00 Vitamin D and cardiovascular disease: A review of the epidemiological and
clinical evidence
R. Scragg (New Zealand)
15:30 Vitamin K and bone health
M.J. Shearer (United Kingdom)
Workshop 14
HALL 10
14:30-16:00
NOVEL INSIGHTS IN IRON METABOLISM: IMPLICATIONS FOR
DIAGNOSTIC MEDICINE
Chairs: D.W. Swinkels (The Netherlands)
14:30 Newly identified inherited disorders of iron metabolism
R. Fleming (USA)
15:00 Anemia of chronic disease: Markers for diagnosis and treatment monitoring
G. Weiss (Austria)
15:30 Hepcidin-25, a new biomarker for differentiation of iron-restricted erythropoiesis
L. Thomas (Germany)
76
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
HALL 1
CLOSING CEREMONY
16:30
Congress Presidents
Rudolf Tauber, Harald Renz
16:40
Welcome to Milano
President of the EuroMedLab Milano 2013
Mauro Panteghini
16:50
Welcome to Istanbul
President of the IFCC WorldLab Istanbul 2014
Nazmi Ozer
17:00
Closing remarks
IFCC / EFCC / DGKL Presidents
Graham Beastall, Rita Horvath, Karl Lackner
17:30
Farewell Istanbul Party
Thurs da y 1 9 May
16:30 - 17:30
See you in
Istanbul 2014
77
Thu rs da y 1 9 Ma y
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
CLOSED MEETINGS
8:00-11:00
Room 47
IFCC TF-PG
Chair. R. van Schaik
14:30-15:30 Room 48
IFCC WG-cMSP
Chair: S. Lehman
8:00-11:00
Room 48
EFCC WG-PEQA
Chair: S. Sandberg
14:30-17:30 Room 47
IFCC TF-CKD
Chair: G. Jones
78
Visit us at IFCC - EuroMedLab
Hall 15 / Booth 15-01a
$! !& " ! "!"%
!# !#
We invite you to attend our workshop :
TLA - The "Lean" Alternative
Tuesday, May, 17 - 16:45 - 17:45 - Hall 8
Presented by Mick CHOMYN & Martin FOTTLES
(Path Links Pathology - UK)
Speak e rs & Cha i r s
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Adeli Khosrow
(page 69)
The Hospital for Sick Children, University of
Toronto, Canada
khosrow.adeli@sickkids.ca
Beaudeux Jean-Louis
(pages 53; 59; 71)
Department of Clinical Biology, Charles Foix
Hospital, Paris, France
jean-louis.beaudeux@cfx.aphp.fr
Aguzzi Adriano
(page 57)
Institute of Neuropathology, Zurich University,
Switzerland
adriano.aguzzi@usz.ch
Becker Stefan
(page 35)
Institut fur Virologie, Philipps Universitat Marburg,
Germany
becker@staff.uni-marburg.de
Ajzner Eva
(page 64)
University of Debrecen, Debrecen, Hungary
ajzner@gmail.com
Benga Gheorghe
(page 34)
First Laboratory of Genetic Explorations, ClujCounty Clinical Emergency Hospital, Romania
gbenga@umfcluj.ro
Alcantara Flavio
(page 71)
Central Laboratory Division, Hosp das Clinicas,
University of Sao Paulo, Brazil
alcantara@hcnet.usp.br
Bidlingmaier Martin
(page 69)
Medizinische Klinik Innenstadt, LudwigMaximilians University, Munich, Germany
Martin.Bidlingmaier@med.uni-muenchen.de
Álvarez Menéndez Francisco (page 25)
Hospital Universitario Central de Asturias, Oviedo,
Spain
falvarezmen@gmail.com
Bieber Thomas
(page 55)
Universitäts-Klinikum Bonn, Germany
Thomas.Bieber@ukb.uni-bonn.de
Anderson Leigh
(page 16)
Plasma Proteome Institute, Washington, USA
leighanderson@plasmaproteome.org
Bischoff-Ferrari Heike
(page 70)
University of Zurich, Switzerland
Heike.Bischoff@usz.ch
Apple Fred
(page 16)
Hennepin County Medical Center and University of
Minnesota, Minneapolis, USA
apple004@umn.edu
Blankenberg Stefan
(page 15)
University Medical Center Mainz, Dept. of
Medicine II, Germany
stefan.blankenberg@unimedizin-mainz.de
Aufenanger Johannes
(page 27)
Institut fur Laboratoriumsmedizin, Klinikum
Ingolstadt, Germany
johannes.aufenanger@klinikum-ingolstadt.de
Blaton Victor
(page 16)
Department of Clinical Chemistry, Brugge,
Belgium
victor.blaton@skynet.be
Bais Renze
(page 40; 70)
Pacific Laboratory Medicine Services Pathology
North, Sydney, Australia
rbais@med.usyd.edu.au
Blum Hubert
(page 15)
Universitäts-Klinikum Freiburg, Germany
Hubert.blum@uniklinik-freiburg.de
Bartlett Bill
(page 64)
Blood Sciences, Diagnostics Group, Ninewells
Hospital and Medical School, NHS Tayside,
Dundee, UK
b.bartlett@dundee.ac.uk
Bauersfeld Walter
(page 18)
Zentrallabr, KKH Lörrach, Germany
bauersfeld.walter@klinloe.de
Beastall Graham H.
(page 19)
Department of Clinical Biochemistry, Macewen
Building Royal Infirmary, Glasgow, UK
gbeastall@googlemail.com
80
Boivin Guy
(page 46)
Laval University, Quebec City, Canada
guy.boivin@crchul.ulaval.ca
Bossuyt Patrick
(page 26)
University of Amsterdam, The Netherlands
p.m.bossuyt@amc.nl
Boyd Jim
(page 45)
Dept. of Pathology, University of Virginia Health
System, Charlottesville, USA
jboyd@virginia.edu
Brand Angela
(page 37)
Institute for Public Health Genomics CIPHal,
Maastricht University, The Netherlands
a.brand@phg.unimaas.nl
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Cross Anne H.
(page 53)
Washington University School of Medicine, Saint
Louis, USA
crossa@neuro.wustl.edu
Bunk David
(page 37)
Analytical Chemistry Division, NIST, Gaithesburg,
USA
david.bunk@nist.gov
Delanghe Joris
(pages 34; 64)
Ghent University Hospital, Ghent, Belgium
joris.delanghe@ugent.be
Cantinotti Massimiliano
(page 69)
Hearth Hospital Massa, National Institute
Research, Massa, Italy
massimiliano.cantinotti@ifc.cnr.it
Dick Wolfgang
(page 18)
Staedtische Kliniken Neuss Zentrallabor, Neuss,
Germany
Wolfgang_Dick@lukasneuss.de
Carayon Pierre
(page 21; 44)
Marseille Medical School and Mediterranean
University Hospital, Marseille, France
pierre.carayon@univmed.fr
Domann Eugen
(page 56)
Institut für Medizinische Mikrobiologie, Molekulare
Diagnostik, Frankfurt, Germany
eugen.domann@mikrobio.med.uni-giessen.de
Carter Graham
(page 70)
Charing Cross Hospital, London, UK
b.carter1@which.net
ElGarf Wael
(page 26)
National Research Center, Medical Research
Division-Reproductive Health Department, DokkiCairo, Egypt
elgarfw@gmail.com
Casadesus Smith Gemma
(page 53)
Case Western Reserve University, Cleveland, USA
gxc40@case.edu
Cavalier Etienne
(page 44)
University of Liege, Chu Sart-Tilman, Belgium
Etienne.cavalier@chu.ulg.ac.be
Ceriello Antonio
(page 35)
Insititut d'Investigacions Biomèdiques August Pi i
Sunyer (IDIBAPS), Barcelona, Spain
Antonio.Ceriello@hotmail.it
Ceriotti Ferruccio
(pages 15; 21; 53)
Diagnostica & Ricerca, San Raffaele, Milano, Italy
ceriotti.ferruccio@hsr.it
Choudhury Robin
(page 15)
University of Oxford, Oxford, United Kingdom
robin.choudhury@cardiov.ox.ac.uk
Christenson Robert
(page 15)
University of Maryland, School of Medicine,
Baltimore, USA
rchristenson@umm.edu
Comabella Manuel
(page 57)
Centre d’Esclerosi Multiple de Catalunya, Hospital
Universitari, Barcelona, Spain
mcomabel@vhebron.net
Croal Bernie
(pages 18; 65)
NHS Grampian, Aberdeen, United Kingdom
bernie.croal@nhs.net
Ferrari Maurizio
(page 37)
Vita-Salute San Raffaele University, Milan, Italy
Ferrari.maurizio@hsr.it
S pe a k e rs & Chairs
Bruns David
(page 34)
University of Virginia, Charlottesville, USA
dbruns@virginia.edu
Fleming Robert
(page 76)
Saint Louis University, School of Medicine, USA
flemingr@slu.edu
Frank Elisabeth
(page 68)
Bio Chem Diagnostics Pvt, Mysore, India
anet21frank@yahoo.com
Freedman Danielle B.
(page 65)
Clinical Biochemistry Luton and Dunstable
Hospital, Luton, United Kingdom
Danielle.Freedman@ldh.nhs.uk
Ganten Detlev
(page 12)
Charité, Universitätsmedizin Berlin, Berlin, Germany
detlev.ganten@charite.de
Gässler Norbert
(page 18)
Zentrum für Labordiagnostik, Hildesheim,
Germany
n.gaessler@bernward-khs.de
Gay Steffen
(page 25)
Dept. Rheum, University Hospital, Zurich,
Switzerland
steffen.gay@usz.ch
Gerlich Wolfram
(page 15)
Institute for Medical Virology, Justus Liebig
University, Giessen, Germany
wolfram.gerlich@viro.med.uni-giessen.de
81
Speak e rs & Cha i r s
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Gillery Philippe
(pages 25; 75)
University Hospital of Reims, France
pgillery@chu-reims.fr
Harmsen Dag
(page 35)
University Munster, Germany
dag.harmsen@ukmuenster.de
Giroud Claude
(page 46)
Bio-Rad, France
Claude.Giroud@bio-rad.com
Haushofer Alexander (page 27)
Hospital St. Poelten, St. Poelten, Austria
Alexander.Haushofer@stpoelten.lknoe.at
Goldsmith Barbara
(page 44)
Clinical and Laboratory Standards Institute (CLSI),
Pennsylvania, Wayne, USA
bgoldsmith@clsi.org
Heck Albert J.R.
(page 72)
Utrecht University, Biomolecular Mass
Spectrometry and Proteomics Group,
The Netherlands
a.j.r.heck@chem.uu.nl
Gouget Bernard
(page 15; 58)
Fédération Hospitalière de France, Paris, France
b.gouget@fhf.fr
Greenberg Neil
(page 17)
Clinical Laboratory Products, Ortho-Clinical
Diagnostics, Inc., Rochester, NY, USA
ngreenbe@ocdus.jnj.com
Griesmacher Andrea (page 27)
Centre Institute of Medical and Chemical
Laboratory Diagnostics, University Hospital of
Innsbruck, Austria
andrea.griesmacher@uki.at
Gronowski Ann
(page 25)
Washington University School of Medicine, St.
Louis, Missouri, USA
gronowski@wustl.edu
Grubb Anders
(page 17)
Department of Clinical Chemistry, University
Hospital, Lund, Sweden
anders.grubb@med.lu.se
Haferlach Torsten
(page 63)
MLL Munich Leukemia Laboratory, Munich, Germany
Torsten.haferlach@mll.com
Haining W. Nicholas (page 38)
Dana-Farber Cancer Institute, Harvard Medical
School, Boston, USA
nicholas_haining@dfci.harvard.edu
Hallaj Zuhair
(page 26)
World Health Organization, Cairo, Egypt
hallajz@emro.who.int
Hallworth Michael
(page 65)
Dept. Clinical Biochemistry, Royal Shrewsbury
Hospital, Shrewsbury, United Kingdom
mike.hallworth@sath.nhs.uk
Harb Fouad
(page 68)
Arab Fed. of Clinical Chemistry, Damascus, Syria
fouad.harb@scs-net.org
82
Helsens Kenny
(page 56)
Computational Omics and Systems Biology Group,
Department of Medical Protein Research, Universiteit
Gent, Belgium
kenny.helsens@ugent.be
Heneghan Carl
(page 26)
Dept. of Primary Health Care and Directory Centre
for Evidence-Based Medicine, Oxford,
United Kingodm
carl.heneghan@dphpc.ox.ac.uk
Herrmann Wolfgang (page 40; 76)
Medical School, Saarland University, Homburg,
Germany
w-herrmann@gmx.de
Hicks Jocelyn J.M.
(page 54)
George Washington University Medical Center,
Washington, USA
hicksjmb@gmail.com
Hiemke Christoph
(page 34)
Department of Psychiatry and Psychotherapy,
University Medical Center, Mainz, Germany
hiemke@mail.uni-mainz.de
Hochstrasser Denis F.
(page 72)
Hopitaux universitaires de Genéve, Switzerland
denis.hochstrasser@unige.ch
Holick Michael F.
(page 34)
Boston University Medical Center, Boston, USA
mfholick@bu.edu; lorrie@bu.edu
Hong Shang
(page 66)
First Hospital, China Medical University,
Shenyang, China
hongshang100@hotmail.com
Hoppe Berthold
(page 58)
Institute of Transfusion Medicine, Campus
Virchow Klinikum, Charité Universitätsmedizin
Berlin, Germany
berthold.hoppe@charite.de
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Horvath Andrea Rita (pages 26; 38; 65)
Seals Department Clinical Chemistry, Prince of
Wales Hospital, Sydney, Australia
rita.horvath@sesiahs.health.nsw.gov.au
Huber Andreas R.
(pages 27; 36)
Kantonsspital, Aarau, Switzerland
andreas.huber@ksa.ch
Hubmann Michael
(page 45)
Medizinisches Zentrallaboratorium, Feldkirch,
Austria
mhubmann@mzl.at
Huestis Marilyn
(page 16)
National Institute on Drug Abuse, Baltimore, USA
mhuestis@intra.nida.nih.gov
Huisman Wim
(page 46)
Clinical Chemistry Laboratory, Medical Center
Haaglanden, Den Haag, The Netherlands
w.huisman@mchaaglanden.nl
Ichihara Kiyoshi
(page 45; 59)
Yamaguchi University Graduate School of
Medicine, Faculty of Health Sciences, Ube, Japan
ichihara@yamaguchi-u.ac.jp
Isermann Berend
(page 65)
Universitatsklinikum Heidelberg, Heidelberg,
Germany
Berend.Isermann@med.uni-heidelberg.de
Jacobs Ellis
(page 17)
New York University, School of Medicine, USA
Ellis.Jacobs@nyumc.org
Jansen Rob
(page 46)
SKML, Nijmegen, The Netherlands
rjansen@skml.nl
John W. Garry
(page 25)
Clinical Biochemistry Norfolic and Norwich
University Hospital, Norwich, United Kingdom
g.john@nnuh.nhs.uk
Jones Graham
(pages 17; 71)
St Vincents Hospital, Sydney, Australia
gjones@stvincents.com.au
Jones Glenville
(page 70)
Department of Biochemistry Queen's University,
Kingston, Canada
gj1@queensu.ca
Kaminski Wolfgang
(page 65)
Institute for Clinical Chemistry, University of
Hedelberg, Mannheim, Germany
Wolfgang.Kaminski@umm.de
Kappelmayer Janos (page 63)
University of Debrecen, Hungary
kappelmayer@med.unideb.hu
Kappert Kai
(page 21)
Zentralinstitut für Laboratoriumsmedizin
Charité, Berlin, Germany
kai.kappert@charite.de
Katus Hugo A.
(page 37)
University Hospital Heidelberg Internal Medicine,
Internal III Cardiology, Germany
Hugo.Katus@med.uni-heidelberg.de
Keith W. Nicol
(page 19)
Institute of Cancer Sciences, Glasgow University,
United Kingdom
n.keith@beatson.gla.ac.uk
Kellogg Mark D.
(page 74)
Children's Hospital Boston, USA
mark.kellogg@childrens.harvard.edu
Kelso Anne
(page 46)
WHO Collaborating Centre for Reference and
Research on Influenza, North Melbourne, Australia
anne.kelso@influenzacentre.org
S pe a k e rs & Chairs
Hornemann Thorsten
(page 65)
Inst. fur Klinische Chemie, Zurich, Switzerland
thorsten.hornemann@usz.ch
Kessler Anja
(page 75)
Reference Institute of Bioanalytics, Bonn,
Germany
anja.kessler@uni-bonn.de
Kessler Harald
(page 68)
Medical University of Graz, Graz, Austria
harald.kessler@medunigraz.at
Khalil El Taher
(page 26)
Institute of Endemic Diseases, Medical Sciences
Campus, Khartoum, Sudan
eltahirk@iend.org
Kiehntopf Michael
(page 20; 37; 39)
Institut für Klinische Chemie und
Laboratoriumsdiagnostik, Jena, Germany
michael.kiehntopf@med.uni-jena.de
Kilpatrick Eric S.
(pages 18; 65)
Dept. of Clinical Biochemistry, Hull Royal Infirmary,
United Kingdom
Eric.Kilpatrick@hey.nhs.uk
83
Speak e rs & Cha i r s
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
King May-Jean
(page 36)
International Blood Group Reference Laboratory,
NHS Blood & Transplant, Bristol, UK
may-jean.king@nhsbt.nhs.uk
Lam Christopher W.K
(page 55)
Macau Institute for Applied Research in Medicine
and Health, Taipa, Macau
wklam@must.edu.mo
Klakow-Franck Regina
(page 27)
Bundesärztekammer, Berlin, Germany
Regina.Klakow-Franck@baek.de
Lämmle Bernhard
(pages 27; 63)
Universitätklinik fur Haematologie, Inselspital,
Bern, Switzerland
bernhard.laemmle@insel.ch
Klouche Mariam
(pages 17; 44)
Laborzentrum Bremen, Germany
mariam.klouche@laborzentrum-bremen.de
Knabbe Cornelius
(page 21; 39)
Institut für Laboratoriums- und Transfusionsmedizin,
Universitätsklinik der Ruhr, Bad Oeynhausen,
Germany
cknabbe@hdz-nrw.de
Langlois Michel
(page 64)
Dept. Laboratory Medicine, Az. St. Jan Hospital,
Bruges, Belgium
michel.langlois@azsintjan.be
Le Roux Carel
(page 44)
Imperial College London, United Kingdom
c.leroux@imperial.ac.uk
Kocna Petr
(page 17)
Charles University, Prague, Czech Republic
kocna@lf1.cuni.cz
Lehmann Sylvain
(page 71)
Hopital St. Eloi-Biochimie, Montpellier, France
s-lehmann@chu-montpellier.fr
Kohlmann Alexander (page 68)
MLL Munich Leukemia Laboratory, Munich, Germany
alexander.kohlmann@mll.com
Libeer Jean-Claude
(page 46)
EFCC Quality Management Committee, Belgium
jclibeer@skynet.be
Kohse Klaus
(page 54; 59)
Klinikum Oldenburg, Germany
Kohse.Klaus@klinikum-oldenburg.de
Lichtinghagen Ralf
(page 18; 21)
Hannover Medical School, Institute of Clinical
Chemistry, Hannover, Germany
lichtinghagen.ralf@mh-hannover.de
Koike Takao
(page 25)
Depart. of Medicine II, Hokkaido University
Graduated School of Medicine, Sapporo, Japan
tkoike@med.hokudai.ac.jp
Kosack Cara
(page 74)
Medicins sans frontieres, Amsterdam,
The Netherlands
cara.kosack@amsterdam.msf.org
Kubista Mikael
(page 68)
Tataa Biocenter, Gothenburg, Sweden
mikael.kubista@tataa.com
Kulasingam Vathany (page 16)
University Health Network and University of
Toronto, Toronto, Canada
vathany.kulasingam@uhn.on.ca
Lackner Karl
(pages 19; 36; 65)
Institute of Clinical Chemistry and Laboratory
Medicine, Medical Center of the J.G. University,
Mainz, Germany
karl.lackner@unimedizin-mainz.de
Laitinen Päivi
(page 70)
Laboratory, Central Ostrobothin Hospital District,
Kokkola, Finland
paivi.laitinen@oulu.fi
84
Linder Mark
(page 34)
University of Louisville, School of Medicine,
Lousville, USA
mwlind01@gwise.louisville.edu
Lippi Giuseppe
(page 53; 70)
U.O. Diagnostica Ematochimica, Azienda
Ospedaliero-Universitaria di Parma, Italy
giuseppe.lippi@univr.it
Little Randie
(page 18)
University of Missouri, School of Medicine,
Columbia, USA
littler@health.missouri.edu
Lo Dennis
(pages 16; 74)
The Chinese University of Hong Kong, China
loym@cuhk.edu.hk
Lopez Joseph
(page 39; 55)
Mahsa University, Petaling Jaya, Malaysia
jblopez@streamyx.com
Lyon Andrew
(page 17)
University of Calgary & Calgary, Lab. Services,
Canada
andrew.lyon@cls.ab.ca
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Müller Mathias M.
(page 38)
Austrian Society of Quality Assurance and
Standardisation, Wien, Austria
mathias.mueller1@chello.at
MacPhee Iain
(page 75)
St. George's, University of London, London, UK
imacphee@sghms.ac.uk
Müller Michael
(page 27)
BDL C.V. Oldenburg, Germany
m.mueller@medlab-oldenburg.de
Majkic-Singh Nada
(page 63)
Institute of Medical Biochemistry, Clinical Center of
Serbia, Belgrade, Serbia
singh@eunet.rs; dmbj@eunet.rs
Muszbek László
(page 63)
University of Debrecen, Medical and Health
Science Center, Debrecen, Hungary
muszbek@med.unideb.hu
Mannhalter Christine (page 68)
Medical University Vienna, Dept. Laboratory
Medicine, Vienna, Austria
christine.mannhalter@meduniwien.ac.at
Neubauer Andreas
(page 63)
Universitatsklinik fur Hematologie, Onkologie,
Immunologia, Marburg, Germany
neubauer@staff.uni-marburg.de
Martins Ralph N.
(pages 53; 57)
Ageing and Alzheimers, Edith Cowan University,
Perth, Australia
r.martins@ecu.edu.au
Neumaier Michael
(pages 16; 37)
University Medicine Mannheim, Mannheim, Germany
michael.neumaier@medma.uni-heidelberg.de
Maurer Hans
(page 74)
Department of Experimental and Clinical Toxicology,
Saarland University, Homburg, Germany
hans.maurer@uks.eu
Mayansky Nikolay
(page 69)
Scientific Center for Children's Health, Moscow,
Russia
mayansky@nczd.ru
Meyer Helmut E.
(page 56)
Ruhr-University of Bochum, Recklinghausen,
Germany
helmut.e.meyer@rub.de
Neurath Markus F.
(page 38)
Department of Medicine 1, University Hospital
Erlangen, Germany
markus.neurath@uk-erlangen.de
Obeid Rima
(page 76)
Department of Clinical Chemistry Central Laboratory,
University of Saarland, Homburg, Germany
rima.obeid@uniklinikum-saarland.de
O'Connor Gavin
(page 69)
Principal Scientist, Mass Spectrometry
LGC, United Kingdom
GOC@lgc.co.uk
Migliarino Gabriel
(page 68)
GMigliarino Consultores, Buenos Aires, Argentina
gmigliarino@gmigliarino.com
Oellerich Michael
(pages 71; 75)
Chemistry, George-August-University, Gottingen,
Germany
moeller@med.uni-goettingen.de
Moraes Figueiredo Luiz Tadeu
(page 56)
University of Sao Paulo, Ribeirao Preto, Brazil
ltmfigue@fmrp.usp.br
Oelmueller Uwe
(page 70)
Qiagen GmbH, Hilden, Germany
Uwe.Oelmueller@qiagen.com
Morris Howard
(page 70)
University of South Australia, Adelaide, Australia
howard.morris@health.sa.gov.au
Ogriseg Martin
(page 45)
Lab. of Clinical Pathology, Ospital of Brixen, Italy
martin.ogriseg@sb-brixen.it
Muckenthaler Martina
(page 36)
Paediatric Oncology, Haematology and
Immunology University of Heidelberg, Germany
Martina.Muckenthaler@med.uni-heidelberg.de
Oldenburg Johannes (page 54)
Institute of Experimental Haematology
and Transfusion Medicine, University Clinic Bonn,
Germany
johannes.oldenburg@ukb.uni-bonn.de
Müller Christian
(page 15)
Univeritatsspital Basel, Switzerland
chmueller@uhbs.ch
S pe a k e rs & Chairs
Macdonald Rainer
(page 45)
Physikalisch-Technische Bundesanstalt (PTB),
Berlin, Germany
Rainer.Macdonald@ptb.de
Oosterhuis Wytze
(page 64)
Atrium Medical Center, Heerlen, The Netherlands
w.oosterhuis@atriummc.nl
85
Speak e rs & Cha i r s
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Oudejans Cees
(page 54; 59)
VU University Medical Center, Amsterdam,
The Netherlands
cbm.oudejans@vumc.nl
Platts-Mills Thomas A. E.
(page 55)
University of Virginia Health system,
Charlottesville, USA
tap2Z@virginia.edu
Ozben Tomris
(page 72)
Akdeniz University, Medical Faculty, Antalya, Turkey
tomris.ozben@unimore.it
Plebani Mario
(pages 53; 64)
University of Padova, Italy
mario.plebani@unipd.it
Ozer Nazmi
(page 17; 58)
Hacettepe University, Faculty of Medicine,
Department of Biochemistry, Sihhiye-Ankara,
Turkey
nozertbd@gmail.com
Polack Fernando P.
(page 46)
Vanderbilt University, Hashville, USA
Malinez@infant.org.ar
Palicka Vladimir
(page 70)
Charles University, Prague, Czech Republic
palicka@lfhk.cuni.cz
Panteghini Mauro
(pages 45; 75)
University of Milan, Milan, Italy
mauro.panteghini@unimi.it
Pantel Klaus
(page 16)
Universitatklinikum Hamburg, Hamburg, Germany
pantel@uke.uni-hamburg.de
Parkes Helen
(page 69)
LGC LTD, Teddington, United Kingdom
helen.parkes@lgc.co.uk
Payne Deborah
(page 55)
American Pathology Partners - Unipath LLC,
Denver, USA
dpayne@unipathllc.com
Pazzagli Mario
(pages 55; 70)
University of Florence, Italy
m.pazzagli@dfc.unifi.it
Perret-Liaudet Armand
(page 71)
Hospices Civils de Lyon, France
armand.perret-liaudet@chu-lyon.fr
Perschel Frank Holger
(pages 40; 58)
Charité, Universitatsmedizin, Berlin, Germany
frank.perschel@charite.de
Picheth Geraldo
(page 64)
Federal University of Parana, Department of
Medical Pathology, Curitiba, Brazil
gpicheth@ufpr.br
Pilonetto Marcelo
(page 46)
Brazilian Society of Clinical Analysis, Brazil
m.pilonetto@pucpr.br
Pirmohamed Munir
(pages 34; 54)
University of Liverpool, United Kingdom
munirp@liverpool.ac.uk
86
Preissner Klaus T.
(page 27)
Justus Liebig Universitat Medical School,
Department Biochemistry, Giessen, Germany
Klaus.T.Preissner@biochemie.med.unigiessen.de
Prinz Nadine
(page 65)
Institute of Clinical Chemistry and Laboratory
Medicine, University Medical Centre Mainz,
Germany
Nad.Prinz@web.de
Psarra Katherina
(page 40; 68)
Evangelismis Hospital, Athens, Greece
stcps@hol.gr; info@eekx-kb.gr
Pulkki Kari
(page 44; 59)
Clinical Chemistry, University of Eastern Finland,
Kuopio, Finland
kari.pulkki@islab.fi
Quadrio Isabelle
(page 71)
Service de Neurobiologie, Centre de Biologie Est,
Hospice Civils de Lyon, France
isabelle.quadrio@chu-lyon.fr
Raabe-Meyer Gisela
(page 18)
Praxis fur Humangenetik, Hannover, Germany
grm@humangenetik-hannover.de
Ratziu Vlad
(page 15)
University Pierre et Marie Curie, Paris, France
vratziu@teaser.fr
Raue Friedhelm
(page 44)
Endocrine Practice, Heidelberg, Germany
friedhelm.raue@raue-endokrinologie.de
Reaman Gregory H. (page 19)
The George Washington University, USA
greaman@cnmc.org
Reguengo Henrique (page 69)
Centro Hospitalar do Porto, Portugal
hlreguengo@gmail.com
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Sandberg Sverre
(page 64; 74)
Laboratory of Clinical Biochemistry, Haukeland
University Hospital, Bergen, Norway
sverre.sandberg@isf.uib.no
Rifai Nader
(pages 16; 64)
Children's Hospital, Boston, USA
Nader.Rifai@tch.harvard.edu
Schimmel Heinz
(page 69)
European Commission, Joint Research Centre,
Geel, Belgium
Heinz.Schimmel@ec.europa.eu
Rogic Dunja
(pages 44; 64)
Clinical Institute for Laboratory Diagnsotics,
University Hospital Zagreb, Croatia
dunjarogic@hotmail.com
Schleicher Erwin
(page 25)
University Clinic Tübinger, Clinical Chemistry,
Tübinger, Germany
erwin.schleicher@med.uni-tuebingen.de
Ronco Claudio
(pages 17; 34)
Department of Nephrology, Dialysis and renal
transplantation, St. Bortolo Hospital, Vicenza, Italy
cronco@goldnet.it
Schmitz Gerd
(page 56)
University Hospital Regensburg, Institute for
Clinical Chemistry and Laboratory Medicine,
Germany
gerd.schmitz@klinik.uni-regensburg.de
Rosendaal Frits R.
(page 63)
Leiden University Medical Ctr, Dept. Clinical
Epidemiology, The Netherlands
f.r.rosendaal@lumc.nl
Rosengren Anders
(page 25)
Lund University Diabetes Centre, Dep. Clinical
Sciences Malmö, Sweden
Anders.Rosengren@med.lu.se
Rousseau Francois
(page 55)
Faculté de Médicine, Université Laval & Chuq,
Québec, Canada
Francois.Rousseau@mac.com
Rueda Jesus
(page 26)
European Diagnostic Manufacturers Association
(EDMA), Brussels, Belgium
j.rueda@edma-ivd.be
Rydén Ingvar
(page 51)
Swedish Society of Clinical Chemistry, Sweden
Ingvar.Ryden@ltkalmar.se
Sack Ulrich
(pages 20; 25)
TRM Leipzig, Germany
Ulrich.Sack@medizin.uni-leipzig.de
Sacks David
(page 25)
National Institutes of Healt, Bethesda, Maryland,
USA
sacksdb@mail.nih.gov
Samuelsson Ola
(page 17)
Department of Nephrology, Sahlgrenska University
Hospital, Goteborg, Germany
ola.samuelsson@vgregion.se
S pe a k e rs & Chairs
Renz Harald
(pages 38; 72)
Institute of Laboratory Medicine and
Pathobiochemistry, Molecular Diagnostics Philipps
University Marburg, Germany
renzh@med.uni-marburg.de
Schuff-Werner Peter
(page 63)
Institute of Clinical Chemistry and Laboratory
Medicine, University of Rostock, Germany
pschuffw@med.uni-rostock.de
Scragg Robert
(page 76)
School of Population Health, University S.
Auckland, New Zealand
r.scragg@auckland.ac.nz
Seccombe David
(page 71)
Canadian External Quality Assessment Laboratory
(CEQAL), Vancouver, Canada
dseccombe@ceqal.com
Shannan Ghassan
(pages 26; 68)
Syrian Clinical Laboratory Association, Damascus,
Syria
ghassanshannan@gmail.com
Shearer Martin J.
(page 76)
GSTS Pathology, St. Thomas’ Hospital, Londo,
United Kingdom
Martin.Shearer@gsts.com
Sheldon Joanna
(page 25)
St. George's Hospital, London, United Kingdom
jsheldon@sgul.ac.uk
Sidransky David
(page 16)
Johns Hopkins School of Medicine Director,
Otolaryingology-Head and Neck Cancer
Research, Baltimore, USA
dsidrans@jhmi.edu
Siekmann Lothar
(page 75)
University of Bonn, Germany
lothar.siekmann@ukb.uni-bonn.de
87
Speak e rs & Cha i r s
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Sierra Amor Rosa
(page 21; 36)
Veracruz, Ver, Mexico
rsierramor@hotmail.com
Simundic Ana-Maria (page 70)
Clinical Institute of Chemistry, University Hospital
"Sestre Milosrdnice", Zagreb, Croatia
am.simundic@gmail.com
Sinha Pranav
(page 21; 40)
IMCL, LKH-Klagenfurt, Austria
pksinha@gmx.net
Skrha Jan
(page 35)
3rd Dept. of Internal Medicine and Laboratory for
Endocrinology & Metabolism, 1st Faculty of
Medicine, Prague, Czech Republic
jan.skrha@lf1.cuni.cz
Smith Janet
(page 74)
Chair IFCC Education and Management Division,
Birmingham, United Kingodm
janmsmith@Talk21.com
Smolen Josef S.
(page 25)
Medical University of Vienna, Hietzing Hospital
Vienna, Austria
josef.smolen@wienkav.at
Sprongl Ludek
(page 46)
Central Laboratory, Sumperk Hospital,
Czech Republic
sprongl@nemspk.cz
Steenkamp Vanessa (page 68)
University of Pretoria, South Africa
vanessa.steenkamp@up.ac.za
Stenman Ulf-Hakan
(page 16)
Dept. of Clinicla Chemistry, Helsinki University,
Finland
ulf-hakan.stenman@hus.fi
StJohn Andrew
(page 26)
Ortho Clinical Diagnostics, Asia Pacific, Australia
ASTJOHN@its.jnj.com
Stowasser Michael
(page 44)
Endocrine Hypertension Research Centre, University
of Queensland, Princess Alexandra Hospital,
Brisbane, Australia
m.stowasser@uq.edu.au
Suerbaum Sebastian (page 35)
Institute of Medical Microbiology and Hospital
Epidemiology, Hannover Medical School,
Germany
suerbaum.sebastian@mh-hannover.de
88
Swinkels Dorine W.
(pages 36; 76)
Department of Laboratory Medicine, Radboud
University Nymegen, The Netherlands
D.Swinkels@labgk.umcn.nl
Sypniewska Grazyna (page 40; 53)
Dept. of Laboratory Medicine, Collegium Medicum
Nicolaus Copernicus University, Bydgoszcz, Poland
grazynaodes@interia.pl
Szekeres Thomas
(page 54)
Clinical Institute for Laboratory Medicine, Wien,
Austria
thomas.szekeres@meduniwien.ac.at
Tate Jill
(page 37; 58)
Chemical Pathology Dept., Pathology
Queensland, Royal Brisbane and Womens'
Hospital, Australia
jill_tate@health.qld.gov.au
Tauber Rudolf
(pages 35; 57)
Zentralinstitut für Laboratoriumsmedizin
Charité Universitätsmedizin Berlin, Berlin, Germany
Rudolf.Tauber@charite.de
Tavora Mira Marcelo (page 56)
Graduate Program in Health Sciences, PUCPR,
Curitiba, Brazil
m.mira@pucpr.br
Thienpont Linda
(pages 44; 75)
Laboratory for Analytical Chemistry, Fac. Pharm.
Sci, Ghent University, Belgium
linda.thienpont@ugent.be
Thiery Joachim
(pages 36; 65)
Institut für Laboratoriumsmedizin, Leipzig, Germany
thiery@medizin.uni-leipzig.de
Thomas Lothar
(page 39; 76)
Krankenhaus Nordwest, Frankfurt, Germany
th-books@t-online.de
Thornalley Paul J.
(page 35)
University of Warwick, Coventry, United Kingdom
P.J.Thornalley@warwick.ac.uk
Tomberg Karel
(page 59; 69)
North Estonia Medical Centre, Tallinn, Estonia
karel.tomberg@regionaalhaigla.ee
Tuma Ulisses
(page 34)
Laboratory Moderno Ltda, Goiania, Brazil
ultuma@terra.com.br
Uges Donald R.A.
(page 74)
University Medical Center Groningen,
The Netherlands
d.r.a.uges@apoth.umcg.nl
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
van den Boom Dirk
(page 54)
Research & Development Sugunam, Inc. 3595
John Hopkins Court, San Diego, USA
dvandenboom@sequenom.com
van Gelder Teunis
(page 75)
Erasmus Medical Center Rotterdam,
The Netherlands
t.vangelder@erasmusmc.nl
van Pelt Hans
(page 20; 74)
U. Diagnsotics, Utrecht, The Netherlands
f2hjvpelt@hetnet.nl
van Schaik Ron
(pages 34; 55)
Dept. Clinical Chemistry, Erasmus University
Medical Center, Rotterdam, The Netherlands
r.vanschaik@erasmusmc.nl
Vaubourdolle Michel (page 15)
Pole de Biologie-Imagine, AP HP, Paris, France
michel.vaubourdolle@sat.aphp.fr
Vissa Varalakshmi
(page 56)
Colorado State University, Fort Collins, USA
Varalakshmi.Vissa@ColoState.edu
Voelkerding Karl V.
(page 72)
ARUP Laboratories, University of Utah, USA
voelkek@aruplab.com
Vogt Wolfgang
(page 45)
Munich, Germany
wolfgang.vogt148@superkabel.de
von Eckardstein Arnold
(page 15; 20)
UniversitätsSpital Zürich, Switzerland
arnold.voneckardstein@usz.ch
Wagener Christoph
(pages 19; 20; 56)
Dept. of Clinical Chemistry, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
wagener@uke.uni-hamburg.de
Wagner Oswald
(page 59; 74)
University of Wien, Austria
oswald.wagner@meduniwien.ac.at
Wald Nicholas
(page 54)
Wolfson Institute of Preventive Medicine, London,
United Kingdom
n.j.wald@qmul.ac.uk
Walter Michael
(pages 39; 58)
Zentralinstitut fur Laboratoriumsmedizin und
Pathobiocemie, Charité, Berlin, Germany
M.Walter@charite.de
Walter Ulrich
(pages 36; 39; 63)
Zentrum Innere Medizin, Universitatsklinikum
Wurzburg, Germany
uwalter@klin-biochem.uni-wuerzburg.de
Wang Qiuquan
(page 74)
Department of Chemistry & the Key Lab of
Analytical Sciences, College of Chemistry and
Chemical Engineering, Xiamen University, China
qqwang@xmu.edu.cn
Watson Ian
(page 44)
Aintree University Hospital NHS Foundation Trust,
Liverpool, United Kingdom
IAN.WATSON@aintree.nhs.uk
Weck Karen
(page 54)
University of North Carolina, Chupel Hill, USA
KWeck@unch.unc.edu
Weigel Günter
(page 27)
Innsbruck Medical University, Inst. for Medicine
and Chem., Austria
guenter.weigel@uki.at
S pe a k e rs & Chairs
Valenta Rudolf
(page 55)
Medical University of Vienna, Austria
rudolf.valenta@meduniwien.ac.at
Weimann Andreas
(page 69)
Central Institute of Laboratory Medicine, Charité
University Medical Center, Berlin, Germany
andreas.weimann@charite.de
Weiss Gunter
(page 76)
Dept. of Internal Medicine, Clinical Immunology
and Infectious Diseases, Innsbruck, Austria
guenter.weiss@i-med.ac.at
Werfel Thomas
(page 55)
Hannover Medical School, Hannover, Germany
werfel.thomas@mh-hannover.de
Wesenberg James
(page 36)
Alberta Health Services Red Deer Regional
Hospital Centre, Canada
jwesenberg@dthr.ab.ca
Westermann Jörg
(page 63)
Charité Universitäts-medizin Berlin, Germany
joerg.westermann@charite.de
Westgard James
(page 53)
University of Wisconsin, Madison, USA
James@westgard.com
89
Speak e rs & Cha i r s
I F C C - W o r l d L a b - E u r o M e d L a b B e r l i n 2 0 11
Wevers Ron
(page 74)
Laboratory Genetic Endocrine and Metabolic
Diseases, Dept. Laboratory Medicine, Univ.
Medical Centre Nymegen, The Netherlands
r.wevers@labgk.umcn.nl
Weykamp Cas W.
(page 18)
Queen Beatrix Hospital, Winterswijk,
The Netherlands
C.W.Weykamp@skbwinterswijk.nl
Whiteley William
(page 53)
MRC Clinician Scientist, University of Edinburgh,
United Kingdom
william.whiteley@ed.ac.uk
Wiegel Bernhard
(pages 27; 45)
German Society for Clinical Chemistry and
Laboratory Medicine, Working Group on
Laboratory Management, Germany
dr.bernhard.wiegel@t-online.de
Wieland Eberhard
(page 40; 59; 75)
Klinikum Stuttgart, Center for Clinical Pathology,
Pharmacy and Hygiene, Germany
e.wieland@klinikum-stuttgart.de
Witte Wolfgang
(page 35)
Robert Koch Institute, Wernigerode Branch,
Germany
wittew@rki.de
Wittwer Carl T.
(page 68)
University of Utah, Salt Lake City, USA
carl.wittwer@path.utah.edu
Wyer Lou Ann
(page 44)
Sentara Helthcare, Norfolk, USA
lawyer@sentara.com
Young Ian
(pages 15; 55; 57)
Centre for Public Health, Queen's University
Belfast, United Kingdom
i.young@qub.ac.uk
Young Donald S.
(page 74)
University of Pennsylvania, Philadelphia, USA
donaldyo@mail.med.upenn.edu
Zahedi Rene
(page 56)
Leibniz, Institut für Analytische, Wissenschaften ISAS - Dortmund, Germany
rene.zahedi@isas.de
90
Zatloukal Kurt
(page 70)
Institute of Pathology, Medical University of Graz,
Austria
kurt.zatloukal@medunigraz.at
Zerah Simone
(page 46)
Laboratory Zerah-Taar-Pfeffer, Paris, France
simone.zerah@wanadoo.fr
Zima Tomas
(pages 16; 20; 35; 54)
First Faculty of Medicine, Prague, Czech Republic
zimatom@cesnet.cz
Zinder Oren
(page 63)
Laboratory Medicine, Faculty of Medicine, the
Technion, Israel Institute of Technology, Haifa,
Israel
ozinder@matav.net.il
Solutions that drive knowledge
Life changing knowledge begins in the laboratory. At Ortho Clinical
Diagnostics, we are leading efficiency and productivity through
innovative technology and high quality services that help you provide
the highest level of care for your patients.
Join us at
booth 17-10
to learn more
Plan to attend the industry-sponsored workshops from Ortho Clinical Diagnostics:
16 MAY | 13:00-14:00 | HALL 8
16 MAY | 15:30-16:30 | HALL 14.2
17 MAY | 13:00-14:00 | HALL 10
Testing for Vitamin D Deficiency:
Defining At-Risk Populations
ENHANCING PATIENT CARE IN
ENHANCING PATIENT CARE IN
THE CHALLENGING DIAGNOSTIC
ARENA IN EUROPE: How to
THE CHALLENGING DIAGNOSTIC
ARENA IN EUROPE: Innovative
Face European Healthcare and
Diagnostics Challenges with Process
Solutions that Maximize Clinical
Laboratory Cost Efficiencies
Technological Platforms and
High Quality Services to Enhance
Productivity in Increasingly
Complex Lab Structures
ISW 1
ISW 9
www.orthoclinical.com
ISW 23
© Ortho-Clinical Diagnostics, Inc., 2011
CL11698
QU
QUALITY
ALITY CONTROL
CONTROL NEEDS T
TO
O BE AS PRECISE AND ACCURATE
ACCURA
ATE
T AS CLOCKW
CLOCKWORK.
WORK.
O
G
GUARANTEE
UA R A N T E E T
THE
HE A
ACCURACY
C C U R AC Y A
AND
ND P
PRECISION
RECISION O
OFF Y
YOUR
OUR T
TEST
E S T RESULTS
R E S U LT S
ANDO
OX
WITH
W I T H RANDO
RANDOX
The extensive Acusera range
ange of Quality Contr
outine and specialized
specializ
parameters. In addition to this our diverse product range guarantees excellent choice, stability and consolidation.
co
With nearly 30 years experience in the diagnostics industry, Ran
Randox understands the importance of
laboratory qualityy, so ever y control we manufacture is to the highest standard.
ss
ss
ss
ss
ss
ss
Third party controls offering unbiased assessment of performance
Most accurate target values based on results from over 16,000 independent laboratories
rial,, with minimal variation between lots
Most consistent material,
x controls will meet and often exceed their stability claims
Most stable material,, Rando
R
Highest quality material with no added preservatives or stabilizers
100% human material will not interfere with antibody based tests
S
IT U 1
S
I
V
.0
ASE ND 15
E
L
P
S TA
15
ON HALL
#
#ONTROLS!VAILABLE
ONTROLS!VAILABLE
#LINICAL#HEMISTRYs)MMUNOASSAYs)MMUNOLOGY0ROTEINSs#ARDIACs,IPIDS
ss#LINICAL#HEMISTRYs)MMUNOASSAYs)MMUNOLOGY0ROTEINSs#ARDIACs,IPIDS
ss$IABETESs5RINE#HEMISTRYs5RINALYSISs4OXICOLOGYs4HERAPEUTIC$RUGS
$IABETESs5RINE#HEMISTRYs5RINALYSISs4OXICOLOGYs4HERAPEUTIC$RUGS
4UMOR-ARKERSs-ATERNAL3CREENINGs#OAGULATIONs"LOOD'AS
ss4UMOR-ARKERSs-ATERNAL3CREENINGs#OAGULATIONs"LOOD'AS
3PECIALITY2ESEARCHs!NTIOXIDANTS
ss3PECIALITY2ESEARCHs!NTIOXIDANTS
Set
Set the
the standard
standard ffor
or good
good quality
quality control
control practice
practice with
with Randox
Randox Acusera
R
Randox
andox Laboratories
Laboratories Limited
Limited
Diamond
iamond R
Road,
oad, C
Crumlin,
r umlin, C
County
ounty A
Antrim,
BT29
United Kingdom
Kingdom
555
5D
ntr im, B
T29 44QY,
QY, United
T +44
+44 (0)
(0) 28
28 9442
9442 2413
2413 F +
+44
44 (0)
(0) 28
28 9445
9445 2912
2912 E
marketing@randox.com
mar keting@r andox.com I w
www.randox.com
ww.r andox.com